A Phase II, Multi-center, Two-Part, Three-Arm, Dose-Ranging Study of the Safety and Efficacy of Leronlimab (PRO 140) in Adult Patients With Nonalcoholic Steatohepatitis (NASH)
Phase: PHASE2
Conditions: Nonalcoholic Steatohepatitis (NASH)
Sponsor: CytoDyn, Inc.

CONFIDENTIAL 
Page 1 of 96 
 
 
 
 
 
A Phase II, Multi-center, Two-Part (Part 1: Randomized, Double-Blind, Placebo- 
Controlled with Leronlimab 700mg and placebo; and Part 2: Open-label, Single Arm with 
Leronlimab 350mg), Three-Arm, Dose-Ranging Study of the Safety and Efficacy of 
Leronlimab (PRO 140) in Adult Patients with Nonalcoholic Steatohepatitis (NASH) 
 
 
 
 
Protocol Number: 
CDI-NASH-01 
Final Version: 
7.0 
Date: 
14-Jun-2021 
 
Sponsor: 
 
CytoDyn, Inc. 
1111 Main Street, Suite 660 
Vancouver, Washington 98660 
(360) 980-8524-Work 
(360) 980-8549-Fax 
www.cytodyn.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confidentiality Statement 
 
This document is a confidential communication of CytoDyn, Inc. It is provided for the conduct of a clinical 
research study. The information contained in this document is confidential and, except to the extent necessary 
to obtain informed consent or IEC/IRB approval, cannot be disclosed unless required by governmental 
regulation. Persons to whom any portion of the contents of this document is disclosed must be informed that 
the information is confidential and may not be further disclosed by them. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 2 of 96 
 
 
 
PROTOCOL APPROVAL PAGE 
 
 
Protocol Number: 
CDI-NASH-01 
Final Version: 
7.0 
Date: 
14-Jun-2021 
 
 
 
We, the undersigned, have reviewed this protocol and agree that it contains all relevant information required to 
meet FDA, GCP and all applicable regulatory guidelines and statutes. 
 
 
PROTOCOL APPROVAL FOR USE 
 
 
 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 3 of 96 
 
 
 
INVESTIGATOR’S SIGNATURE PAGE 
 
 
Protocol Number: 
CDI-NASH-01 
Final Version: 
7.0 
Date: 
14-Jun-2021 
 
 
 
 
 
I have read the protocol specified above and agree to participate in and comply with the procedures, as outlined 
herein for the conduct of this clinical trial. I also agree to comply with US Food and Drug Administration (FDA) 
regulations and Investigational Review Board/Institutional Ethics (IRB/IEC) requirements for testing on human 
subjects. I agree to ensure that the requirements for obtaining informed consent are met. 
 
 
 
 
 
 
 
 
Principal Investigator’s Signature 
 
Date 
Print Name 
 
 
Site Number 
 
 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 4 of 96 
 
 
 
SPONSOR INFORMATION 
CytoDyn, Inc. 
 
1111 Main Street, Suite 660 
Vancouver, Washington 98660 
(360) 980-8524-Work 
(360) 980-8549-Fax 
www.cytodyn.com 
 
 
 
 
 
 
 
 
 
 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 7 of 96 
 
 
 
mg dose) will be weekly administered subcutaneously (SC) by a licensed healthcare professional at the clinic 
sites. 
 Part 1: randomized, double-blind, placebo-controlled, two-arm (up to 60 subjects) 
 
Leronlimab (PRO 140 700 mg) or Placebo SC weekly injection for 13 weeks 
 Part 2: non-randomized, open-label, single-arm (up to 30 subjects) 
 
Leronlimab (PRO 140 350 mg) SC weekly injection for 13 weeks 
This study consists of screening, treatment, and follow-up periods. 
Screening Period (Up to 4 weeks): 
Screening assessments will commence after obtaining signed Informed Consent Form (ICF), and review of 
medical history, demographic information, baseline disease characteristics, eligibility evaluation, physical 
examination, vital signs, height and weight, prior and concomitant medications, electrocardiogram (ECG), 
Liver MRI, FibroScan (or equivalent non-invasive imaging test), FibroTest, routine serum biochemistry 
including liver function test, hematology, HIV and hepatitis serology panel, urinalysis, serum pregnancy (if 
applicable). These assessments must be conducted within 28 days of the first treatment visit. Subjects who 
fail to meet eligibility criteria will be considered screen failures and exit the study without any further 
evaluations. 
Treatment Period (Up to 14 Weeks): 
In the Part 1 of the study, subjects who meet all eligibility criteria, as per data gathered from Screening Visit, 
will be randomized 1:1 to one of the two study arms to receive Leronlimab 700 mg (Group A), or placebo 
(Group B) during the treatment period. 
 
PRO 140 (700mg) SC weekly injection (Group A) 
 
Placebo (0 mg) SC weekly injection (Group B) 
Study treatments for each group (Leronlimab 700 mg or placebo) will be subcutaneously administered every 
week by a licensed healthcare professional at the study site for 13 weeks. The End of Treatment (EOT) visit 
(or early withdrawal visit in case of patients withdrawn prematurely from the study) will happen 1 week 
after receiving the last study treatment. 
In the non-randomized, single-arm, open-label phase (Part 2) of the study, leronlimab (PRO 140 350 mg 
dose) will be weekly administered subcutaneously (SC) by a licensed healthcare professional at the clinic 
sites for 13 weeks. 
Follow-Up Period: 
A Follow-Up visit will be conducted 28 (± 3) days after the End of Treatment (EOT) or Early Termination 
(ET) Visit. 
Duration of Treatment: 
 
Screening Period: Up to 4 weeks 
 
Treatment Period: Up to 14 weeks 
 
Follow-Up Period: Up to 4 weeks after End of Treatment (EOT) or Early Termination (ET) Visit 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 12 of 96 
 
 
 
TABLE OF CONTENTS 
PROTOCOL SYNOPSIS ............................................................................................................... 5 
TABLE OF CONTENTS ............................................................................................................. 12 
List of Tables ................................................................................................................................. 17 
List of Figures ................................................................................................................................ 18 
List of Abbreviations ..................................................................................................................... 19 
1 INTRODUCTION AND BACKGROUND .......................................................................... 23 
1.1 
Statement of Intent ............................................................................................................... 23 
1.2 
Background of the Disease .................................................................................................. 23 
Inflammatory response in nonalcoholic steatohepatitis (NASH) ......................................... 23 
1.3 
Study Treatment ................................................................................................................... 24 
Leronlimab (PRO 140) ........................................................................................................ 24 
1.4 
Pre-Clinical Studies of Leronlimab (PRO 140) ................................................................... 24 
Non-Clinical Studies with Leronlimab (PRO 140) on NASH ............................................. 25 
1.5 
Clinical Studies with Leronlimab (PRO 140) ...................................................................... 25 
PRO 140 1101 Study ........................................................................................................... 25 
PRO 140 1102 Study ........................................................................................................... 26 
PRO 140 1103 Study ........................................................................................................... 26 
PRO 140 1302 Study ........................................................................................................... 26 
PRO 140 2301 Study ........................................................................................................... 26 
PRO 140 2101 Study ........................................................................................................... 27 
PRO 140_CD01 Study ......................................................................................................... 27 
PRO 140_CD01 Extension Study ........................................................................................ 28 
PRO 140_CD02 Study ......................................................................................................... 29 
PRO 140_CD06 Study ......................................................................................................... 30 
PRO 140_CD02 Extension Study ........................................................................................ 30 
PRO 140_CD03 HIV Study ................................................................................................. 30 
PRO 140_CD03 HIV Extension Study ................................................................................ 31 
CD07_TNBC Study ............................................................................................................. 31 
CD08_mCRC Study ............................................................................................................ 31 
1.6 
Dose Section Rationale ........................................................................................................ 34 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 13 of 96 
 
 
1.7 
Risks / Benefits Assessment ............................................................................................... 36 
Risks/Discomfort to Subjects and Precautions to Minimize Risk ....................................... 36 
Intended Benefit for Subjects .............................................................................................. 37 
2 STUDY OBJECTIVES ......................................................................................................... 38 
2.1 
Primary Objective ............................................................................................................... 38 
2.2 
Secondary Objective: .......................................................................................................... 38 
3 STUDY DESIGN ................................................................................................................... 39 
3.1 
Study Centers ...................................................................................................................... 39 
3.2 
Study Population ................................................................................................................. 39 
3.3 
Eligibility Criteria ............................................................................................................... 41 
Inclusion Criteria ................................................................................................................ 41 
Exclusion Criteria ............................................................................................................... 42 
4 STUDY SCHEDULE ............................................................................................................ 45 
4.1 
Screening Period ................................................................................................................. 50 
Screening Visit ................................................................................................................... 50 
4.2 
Treatment Period ................................................................................................................ 51 
Treatment Visit 1 (T1) ........................................................................................................ 52 
Treatment Visit 2 (T2) to Treatment Visit 13 (T13) ........................................................... 53 
End of Treatment (EOT) Visit ............................................................................................ 54 
Early Termination (ET) Visit .............................................................................................. 55 
4.3 
Follow-Up Period ............................................................................................................... 55 
4.4 
Unscheduled Visits ............................................................................................................. 56 
5 SUBJECT COMPLETION, WITHDRAWAL AND CRITERIA FOR STOPPING THE 
STUDY ................................................................................................................................... 57 
5.1 
Subject Withdrawal ............................................................................................................. 57 
5.2 
Subject Replacement ........................................................................................................... 59 
5.3 
Data Collected from Withdrawn Subjects .......................................................................... 59 
5.4 
Screen Failures .................................................................................................................... 59 
5.5 
Clinical Trial Stopping Criteria .......................................................................................... 60 
6 STUDY TREATMENT ......................................................................................................... 61 
6.1 
Investigational Product ....................................................................................................... 61 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 14 of 96 
 
 
Leronlimab (PRO 140) ........................................................................................................ 61 
Placebo 
61 
6.2 
Leronlimab (PRO 140) - Packaging and Labeling .............................................................. 62 
6.3 
Leronlimab (PRO 140) - Storage and Handling .................................................................. 63 
6.4 
Investigational Product Administration ................................................................................. 63 
Post Injection Monitoring .................................................................................................... 64 
Dose Modifications .............................................................................................................. 64 
6.5 
Investigational Product Disposition ...................................................................................... 65 
6.6 
Investigational Product Accountability ................................................................................. 65 
7 DESCRIPTION OF PROTOCOL ASSESSMENTS AND PROCEDURES ..................... 66 
7.1 
Informed Consent ................................................................................................................ 66 
7.2 
Assessment of Eligibility ..................................................................................................... 66 
Re-screening ........................................................................................................................ 66 
7.3 
Demographic Information and Baseline Disease Characteristics ........................................ 66 
7.4 
Medical History ................................................................................................................... 67 
7.5 
Concomitant Medication ...................................................................................................... 68 
Permitted Medications ......................................................................................................... 68 
Prohibited Medications ........................................................................................................ 68 
7.6 
Vital Signs, Height and Weight ........................................................................................... 69 
7.7 
Physical Examination .......................................................................................................... 69 
7.8 
Electrocardiogram (ECG) .................................................................................................... 70 
7.9 
Clinical Laboratory Assessments ......................................................................................... 70 
Sample Collection Guidelines ............................................................................................. 73 
Sample Processing, Storage, and Shipment ......................................................................... 73 
7.10 Study Treatment Application ............................................................................................... 73 
7.11 Post-Injection Evaluation and Injection Site Reaction Assessment ..................................... 73 
7.12 Pain Severity Assessment .................................................................................................... 73 
7.13 Fibroscan .............................................................................................................................. 74 
7.14 Liver MRI (MultiScan) ........................................................................................................ 74 
8 STATISTICAL ANALYSIS .................................................................................................. 75 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 15 of 96 
 
 
8.1 
Treatment Groups ................................................................................................................ 75 
8.2 
Study Outcome Measures ..................................................................................................... 75 
Primary Efficacy Outcome Measure .................................................................................... 75 
Secondary Efficacy Outcome Measures: ............................................................................. 75 
Exploratory Outcome Measures .......................................................................................... 75 
8.3 
Sample Size Determination and Rationale .......................................................................... 76 
8.4 
Randomization ..................................................................................................................... 76 
8.5 
Blinding ............................................................................................................................... 76 
8.6 
Interim Analysis ................................................................................................................... 76 
8.7 
General Statistical Considerations ........................................................................................ 76 
Analysis Populations ............................................................................................................ 77 
Intent-to-Treat Population ..................................................................................................... 77 
Per Protocol Population ....................................................................................................... 77 
Safety Population ................................................................................................................. 77 
Covariates 77 
Missing Data ........................................................................................................................ 77 
8.8 
Analysis Methods ................................................................................................................ 77 
Subject Disposition .............................................................................................................. 78 
Demographic and Baseline Disease Characteristics ............................................................ 78 
Study Analyses .................................................................................................................... 78 
Efficacy Analysis ................................................................................................................. 78 
Safety Analyses ................................................................................................................... 78 
9 ADVERSE EVENTS (DEFINITIONS AND REPORTING) .............................................. 80 
9.1 
Adverse event (AE) ............................................................................................................. 80 
9.2 
Reporting and Follow-Up of Adverse Events ...................................................................... 80 
Impact on Study Treatment .................................................................................................. 80 
CTCAE Grade (Intensity) Assessment ................................................................................. 81 
Causality Assessment .......................................................................................................... 81 
Treatment Given as a Result of the Event ........................................................................... 82 
Outcome Assessment ........................................................................................................... 82 
Injection-site reactions ......................................................................................................... 82 
9.3 
Serious Adverse Events ....................................................................................................... 82 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 16 of 96 
 
 
9.4 
Reporting of Serious Adverse Events .................................................................................. 83 
9.5 
SAE Follow-Up ................................................................................................................... 83 
9.5.1. 
Regulatory Reporting Requirements for SAEs .................................................. 84 
9.6 
Pregnancy Reporting ............................................................................................................ 84 
10 DIRECT ACCESS TO SOURCE DATA/DOCUMENTATION ........................................ 85 
11 QUALITY CONTROL AND QUALITY ASSURANCE .................................................... 86 
11.1 Monitoring Requirements .................................................................................................... 86 
11.2 Acceptability of Case Report Forms (CRFs) ....................................................................... 86 
11.3 Modification of Protocol ...................................................................................................... 86 
11.4 Reporting Protocol Deviations ............................................................................................. 87 
Major Protocol Deviation or Violation ................................................................................ 87 
Minor Protocol Deviation or Violation ................................................................................ 87 
12 ETHICS AND REGULATORY REQUIREMENTS .......................................................... 89 
12.1 Institutional Review Board/Independent Ethics Committee (IRB/IEC) .............................. 89 
12.2 Investigator’s Responsibilities ............................................................................................. 89 
12.3 Subject Informed Consent Requirements ............................................................................ 90 
13 DATA HANDLING AND RECORD KEEPING ................................................................. 91 
13.1 Recording and Collection of Data ....................................................................................... 91 
13.2 Clinical Data Management .................................................................................................. 91 
13.3 Archiving ............................................................................................................................. 92 
14 PUBLICATION PLAN .......................................................................................................... 93 
15 REFERENCES ....................................................................................................................... 94 
16 APPENDIX ............................................................................................................................. 95 
16.1 Appendix 1: Acceptable Methods of Contraception ........................................................... 95 
16.2 Appendix 2: Common Terminology Criteria for Adverse Events v5.0 ............................... 96 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 17 of 96 
 
 
 
LIST OF TABLES 
Table 1-1: 
List of Completed Clinical Studies with Leronlimab (PRO 140) ........................... 32 
Table 1-2: 
List of Ongoing Clinical Studies with Leronlimab (PRO 140) ............................... 33 
Table 4-1: 
Treatment Groups ................................................................................................... 45 
Table 4-2: 
Schedule of Assessments ........................................................................................ 47 
Table 6-1: 
Treatment Administration Summary ...................................................................... 61 
Table 6-2: 
Part 1: Investigational Product - Leronlimab (PRO 140) or Placebo ...................... 62 
Table 6-3: 
Part 2: Investigational Product - Leronlimab (PRO 140) ........................................ 62 
Table 6-4: 
Leronlimab (PRO 140) Dose Modification and Management for Injection Site 
Reactions ................................................................................................................. 65 
Table 7-1: 
Central Lab Parameters ........................................................................................... 72 
Table 9-1: 
CTCAE v5.0 General Guidelines ........................................................................... 81 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 18 of 96 
 
 
 
 
 
LIST OF FIGURES 
Figure 3-1: 
Study Design Schematic .......................................................................................... 40 
Figure 6-1: 
Investigational Product - Vial Label ........................................................................ 63 
Figure 6-2: 
Investigational Product - Kit Label .......................................................................... 63 
Figure 7-1: 
11-Point Numeric Pain Rating Scale ....................................................................... 73 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 19 of 96 
 
 
LIST OF ABBREVIATIONS 
 
Abbreviation 
Term 
ADA 
Anti-Drug Antibodies 
AE 
Adverse Event 
AASLD 
American Association for the Study of Liver disease 
ALP 
Alkaline Phosphatase 
ALT 
Alanine Aminotransferase 
ANCOVA 
Analysis of Covariance 
ART 
Antireteroviral therapy 
AST 
Aspartate Aminotransferase 
BUN 
Blood Urea Nitrogen 
BMI 
Body Mass Index 
BLM 
Baseline Measurement 
CAP 
Controlled Attenuation Parameter 
CBC 
Complete Blood Count 
CBR 
Clinical Benefit Rate 
CCL5 
C-C Chemokine Ligand Type-5 (RANTES) 
CCR5 
C-C Chemokine Receptor Type-5 
CFR 
Code of Federal Regulations 
CHO 
Chinese Hamster Ovary 
CK 
Creatine Kinase 
CK-18 
Cmax 
Cytokeratin 18 
Maximal Concentration 
CNS 
Central Nervous System 
CRA 
Clinical Research Associate 
CRF 
Case Report Form 
CRO 
cT1 
CTCAE 
Contract Research Organization 
Corrected T1 
Common Terminology Criteria for Adverse Events 
CVD 
Cardiovascular Disease 
D/M 
Dual/Mixed 
DILI 
Drug- Induced Liver Injury 
ECG 
Electrocardiogram 
ECL2 
ExtraCellular Loop 2 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 20 of 96 
 
 
 
 
Abbreviation 
Term 
eCRF 
Electronic Case Report Form 
EASL 
European Association for the Study of the Liver 
eGFR 
Estimated Glomerular Filtration Rate 
EGFR 
Epidermal Growth Factor Receptor 
ELF Score 
Enhanced Liver Fibrosis Score 
EOT 
End of Treatment 
ET 
Early Termination 
F1-F4 
Fibrosis (Stage) 
FDA 
U.S. Food and Drug Administration 
Flu-Mist 
Influenza Vaccine 
FOCBP 
Females of Child-bearing Potential 
GCP 
Good Clinical Practice 
GGT 
Gamma-Glutamyltransferase 
GMP 
Good Manufacturing Practice 
GVHD 
Graft versus Host Disease 
HAV 
Hepatitis A Virus 
HbA1c 
Hemoglobin A1c 
HBsAg 
Hepatitis B Virus Surface Antigen 
HCC 
Hepatocellular Carcinoma 
HCV 
Hepatitis C Virus 
HEENT 
Head, Ears, Eyes, Nose, and Throat 
HEV 
Hepatitis E Virus 
HIPAA 
Health Insurance Portability and Accountability Act 
HIV-1 
Human Immunodeficiency Virus Type 1 
HSC 
Hepatic Stellate Cells 
IA 
Interim Analysis 
ICF 
Informed Consent Form 
ICH 
International Council for Harmonisation 
IEC 
Independent Ethics Committee 
IHC 
Immunohistochemistry assay 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 21 of 96 
 
 
 
 
Abbreviation 
Term 
IND 
INR 
Investigational New Drug 
International Normalized Ratio 
IP 
Investigational Product 
IRB 
Institutional Review Board 
ISR 
Injection Site Reactions 
ITT 
Intent-to-Treat 
IV 
KC 
Intravenous 
Kupffer cell 
kPa 
kilopascals 
LDL 
Low Density Lipoprotein 
LTF 
Lost to Follow-up 
mAb 
Monoclonal Antibody 
mCRC 
Metastatic Colorectal Cancer 
MedDRA 
Medical Dictionary for Regulatory Activities 
M/F 
MRI 
Male/Female 
Magnetic Resonance Imaging 
MSS 
Microsatellite Stable 
MTD 
Maximum Tolerated Dose 
mTNBC 
Metastatic Triple-Negative Breast Cancer 
NAFLD 
NASH 
Nonalcoholic Fatty Liver Disease 
Nonalcoholic Steatohepatitis 
NOAEL 
No Observed Adverse Effect Level 
NCS 
Not Clinically Significant 
Nt 
N terminus 
OBT 
Optimized Background Therapy 
OELF Score 
Original European Liver Fibrosis Panel Score 
ORR 
Overall Response Rate 
OTC 
Over the Counter 
PD 
Pharmacodynamics 
PDFF 
Proton derived fat fraction 
PI 
Principal Investigator 
PK 
Pharmacokinetics 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 22 of 96 
 
 
 
 
Abbreviation 
Term 
PP 
Per Protocol 
PT 
Preferred Term 
QTc 
QT interval corrected for heart rate 
RNA 
Ribonucleic Acid 
SAE 
Serious Adverse Event 
SAP 
Statistical Analysis Plan 
SC 
Subcutaneous 
SOC 
System Organ Class 
SOP 
T3 
T4 
Standard Operating Measures 
Triiodothyronine 
Thyroxine 
TBL 
Total Bilirubin 
T2DM 
Type 2 Diabetes Mellitus 
TEAE 
TSH 
Treatment Emergent Adverse Event 
Thyroid-Stimulating Hormone 
ULN 
Upper Limit Normal 
US 
United States 
USP 
United States Pharmacopeia 
VEGF 
Vascular Endothelial Growth Factor 
VL 
Viral Load 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 23 of 96 
 
 
 
1 
INTRODUCTION AND BACKGROUND 
 
1.1 
STATEMENT OF INTENT 
The design, conduct and reporting of this study shall be conducted in compliance with the protocol, 
International Council for Harmonisation/Good Clinical Practice (ICH/GCP), and all appropriate 
regulatory requirements. Investigator(s) participating in this study will have documented training 
in GCP. Independent monitoring of the trial will be accomplished utilizing a Contract Research 
Organization (CRO). 
 
1.2 
BACKGROUND OF THE DISEASE 
Nonalcoholic steatohepatitis (NASH) is a chronic liver disease characterized histologically by the 
presence of hepatic inflammation and cell injury (hepatocellular ballooning) due to hepatic fat 
accumulation (steatosis) equal or superior to 5% of hepatocytes. NASH develops in the absence of 
excessive alcohol consumption but is linked to unhealthy eating habits and lack of physical activity. 
It is often referred to as metabolic disease of the liver (Naga Chalasani, 2018). NASH can progress 
to high-burden conditions such as cirrhosis, end stage liver disease and Hepatocellular Carcinoma 
(HCC) (Manca Povsic, 2019). It is predicted that NASH will become the leading cause of liver 
transplantation by 2020 in the United States. It is the most common form of chronic liver disease, 
affecting about one-quarter of the population in the United States. An estimated 3-7% of the adult 
population develop NASH, of which approximately 15-20% progress to advanced fibrosis or 
cirrhosis (Zobair M. Younossi, 2018). Despite its very high burden, there are currently no approved 
pharmacological therapies for NASH. Available therapies focus solely on treating NASH 
comorbidities, such as obesity, Type 2 Diabetes Mellitus (T2DM) and Cardiovascular Disease 
(CVD), while NASH management options focus on lifestyle changes, based on diet and exercise, 
and control of the associated comorbidities. Lifestyle changes have demonstrated greatest benefit in 
improving steatosis and mild fibrosis; however, as patients with advanced fibrosis due to NASH are 
at a significantly higher risk of liver-related mortality, pharmacological treatments are urgently 
needed. 
Inflammatory response in nonalcoholic steatohepatitis (NASH) 
In NASH, liver homeostasis is impaired due to an accumulation of toxic lipids. Certain gut bacteria- 
derived products can also penetrate in the liver, where they activate immune responses. This 
contributes to local inflammation of hepatic tissue. This pathological environment provokes 
hepatocytes damage and leads to a state called ballooning. Steatosis, inflammation and ballooning 
are the three lesions that define NASH histologically. 
The inflammatory response to hepatocyte injury plays a key role in hepatic fibrogenesis and involves 
recruitment of inflammatory cells to the site of injury. Recruitment of extra-hepatic inflammatory 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 24 of 96 
 
 
 
cells to the site of hepatic injury is largely mediated by interactions between chemokines and their 
receptors. Monocytes, Kupffer cells (KCs) and Hepatic Stellate Cells (HSCs) can express C-C 
chemokine receptor types 5 (CCR5) on their surface. Evidence implicates CCR5 and their ligands 
including C-C chemokine ligand type 5 (CCL5) in the pathogenesis of liver fibrosis following liver 
injury. 
It has also been shown that patients with chronic liver disease show high levels of CCR5 and CCL5, 
thus showing the role of CCR5 and its ligands in liver fibrosis. Numerous studies of NASH with 
other CCR5 agents have shown anti-inflammatory and anti-fibrotic effects (Lefebvre E, 2016). For 
that reason, CCR5 has become an attractive target for developing new antifibrotic therapies (Zobair 
M. Younossi, 2018). 
 
1.3 
STUDY TREATMENT 
 
Leronlimab (PRO 140) 
Leronlimab (PRO 140) is a humanized IgG4, Monoclonal Antibody (mAb) to the C-C chemokine 
receptor type 5 (CCR5), under development as a therapy for Human Immunodeficiency Virus 
(HIV) infection and other indications including triple negative breast cancer, colorectal cancer and 
Graft versus Host Disease (GVHD). 
Leronlimab (PRO 140) has been administered intravenously or subcutaneously to more than 750 
healthy and HIV-1 infected individuals in Phase I/II/III studies. The drug has been well tolerated 
following intravenous administration of single doses of 0.5 to 10 mg/kg or up to 700 mg weekly 
doses as Subcutaneous (SC) injection. Overall, more than 300 subjects have been exposed to 
Leronlimab (PRO 140) 350 mg SC weekly dose with the longest duration of exposure lasting more 
than 5 years. Similarly, more than 250 and 150 subjects have been exposed to Leronlimab (PRO 140) 
525 mg and 700 mg SC weekly dose, respectively. To date, the longest exposure to PRO 140 525 mg 
and 700mg SC weekly dose is more than 2 years and 48 weeks, respectively. Considering its anti-CCR5 
activity and per the pre-clinical studies conducted, Leronlimab (PRO 140) is being developed as a 
potential therapy for liver fibrosis and inflammation conditions, including NASH. 
 
1.4 
PRE-CLINICAL STUDIES OF LERONLIMAB (PRO 140) 
In vitro and in vivo preclinical studies have been conducted to determine the pharmacokinetic, 
immunogenicity, and toxicity profiles of Leronlimab (PRO 140) following Intravenous (IV) and 
SC administration. Several acute and chronic toxicity studies have been conducted to support the 
clinical development plan. 
Acute toxicity of Leronlimab (PRO 140) was evaluated in New Zealand rabbits, following IV 
administration of 5 or 15 mg/kg. Chronic toxicity was evaluated in cynomolgus monkeys following 
biweekly administration of IV doses up to 10 mg/kg for six months and biweekly administration of 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 25 of 96 
 
 
 
various SC doses up to 50 mg/kg for 24 weeks. The drug was generally well tolerated. Biweekly 
administration of IV doses up to 10 mg/kg for six months resulted in minimum to mild lymphoid 
hyperplasia in assorted lymph nodes and spleen, which was considered an expected immune 
response to a foreign protein. Biweekly administration of SC doses up to 50 mg/kg for 24 weeks 
resulted in minimum injection-site reactions (minimal, multifocal, mononuclear cell infiltrates in 
the subcutis), which were considered due to an inflammatory response to the injected antigen. 
Monkeys tolerated treatment with Leronlimab (PRO 140) for 24 weeks without evidence of local 
or systemic toxicity. Leronlimab (PRO 140) caused no mortality, cageside observations, in-life 
injection-site observations, or gross pathologic findings. Chronic treatment with Leronlimab (PRO 
140) did not affect body weight, food consumption, hematology, clinical chemistry or coagulation 
parameters. 
Both IV and SC administration resulted in elimination half-lives of approximately 200 hours, and 
overall exposure increased with increasing doses. Following SC administration of Leronlimab (PRO 
140) in monkeys, the maximal concentration (Cmax) was achieved within 56 hours and bioavailability 
for Leronlimab (PRO 140) after SC dosing was approximately 70%. 
Non-Clinical Studies with Leronlimab (PRO 140) on NASH 
An in vivo study was conducted to determine the anti-fibrotic activity of PRO 140 humanized 
monoclonal antibody against CCR5 in mouse xenograft models of NASH (Study No.20127293). 
The objective of this study was to assess the effect of PRO 140 on NASH in mice when given by 
intraperitoneal injection bi-weekly for 4 weeks. 
Reduction in liver fibrosis was observed when 2mg PRO 140 was administered via intraperitoneal 
injection twice weekly for 4 weeks 
 
1.5 
CLINICAL STUDIES WITH LERONLIMAB (PRO 140) 
Current human experience with Leronlimab (PRO 140) consists of ten completed and six ongoing 
clinical trials, mostly on healthy subjects or HIV-1 positive subjects. These studies are summarized 
in Table 1-1 and Table 1-2. In all clinical trials, the majority of Adverse Events (AEs) have been 
mild or moderate. No dose-limiting toxicities or patterns of drug-related toxicities were observed. 
PRO 140 1101 Study 
For the first-in-human trial, PRO 140 1101, the drug was administered IV at 0.1, 0.5, 2.0, or 5.0 
mg/kg to healthy subjects and was generally well tolerated, non-immunogenic, and without 
clinically relevant toxicity. Treatment Emergent Adverse Events (TEAEs) did not increase with 
rising PRO 140 dose levels. Seventy-five percent (75%) of subjects reported TEAEs, most of which 
were deemed unrelated to study treatment by the investigator. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 26 of 96 
 
 
 
PRO 140 1102 Study 
For PRO 140 1102, the majority of AEs, other than injection-site reactions, were considered mild 
and possibly related to drug administration. The majority of injection-site reactions were considered 
mild, self-resolving, and definitely related to drug administration. PRO 140 derived from Chinese 
Hamster Ovary (CHO) cells and administered at 100 mg/mL was generally well tolerated in 
healthy, normal volunteers. Overall, PRO 140 administered SC using Autoject® 2 appeared better 
tolerated than manual injection. 
PRO 140 1103 Study 
In PRO 140-1103, administration of PRO 140 at 350 mg using Autoject® 2 appeared well tolerated. 
Manual injections, on the other hand, were associated with a greater number of AEs. There did not 
appear, however, to be any substantial difference in subject perception of pain or discomfort related 
to site of drug administration. No anti-PRO 140 antibodies were detected in any subjects in this 
study. There was a tendency of higher exposure associated with SC administration of PRO 140 at 
350 mg in the abdomen and the thigh. A higher number of AEs was associated with injections in 
the arm. Based on these observations, thigh and abdominal administration of PRO 140 were 
preferred over arm injection. 
PRO 140 1302 Study 
The initial proof-of-concept study was a randomized, double-blind, placebo-controlled study in 
subjects with early-stage, asymptomatic HIV infection, only R5 HIV-1 detectable, and no 
antiretroviral therapy for 12 weeks [Jacobson, 2008]. Subjects (n=39) were randomized to receive 
a single IV injection of placebo or PRO 140 at doses of 0.5, 2, or 5 mg/kg. Subjects were monitored 
for antiviral effects, safety, and PRO 140 Pharmacokinetics (PK) for 58 days. 
PRO 140 demonstrated potent, rapid, prolonged, and dose-dependent antiviral activity. Intravenous 
PRO 140 was generally well tolerated. No drug-related serious events or dose-limiting toxicity was 
observed [Jacobson, 2008]. The most common adverse events (headache, lymphadenopathy, 
diarrhea, and fatigue) were observed at similar frequencies across the placebo and PRO 140 dose 
groups. There was no significant effect on QTc intervals or other electrocardiographic parameters, 
and there were no remarkably laboratory findings. 
PRO 140 2301 Study 
PRO 140 2301 was a multi-center, randomized, double-blind, placebo-controlled, parallel group 
study in 30 male and female adult subjects infected with HIV-1 [Jacobson, 2010]. Subjects were 
randomized to one of three groups (N=10/group), each receiving one of three treatments: (i) a single 
IV dose of 5 mg/kg by 30-minute IV infusion; (ii) a single IV dose of 10 mg/kg by 30-minute IV 
infusion; (iii) a single placebo dose by 30-minute IV infusion. The objective of the study was to 
assess and characterize the Pharmacokinetics (PK) and Pharmacodynamics (PD) of PRO 140 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 27 of 96 
 
 
 
administered by IV infusion, assess efficacy at a new dosage level, and safety and tolerability of 
single doses of PRO 140. 
All PRO 140-treated subjects had more than 10-fold reduction in viral loads [Jacobson, 2010]. Both 
the 5 mg/kg and 10 mg/kg doses have shown favorable tolerability and no dose-limiting toxicity 
has been observed. High levels of receptor occupancy (>85% reduction in the number of cells 
detected) were observed for 29 days after treatment with both 5 and 10 mg/kg doses. 
PRO 140 2101 Study 
A subcutaneous (SC) form of PRO 140 was tested in HIV-infected subjects. The trial was a 
randomized, double-blind, placebo-controlled study in subjects (n=44) with early-stage, 
asymptomatic HIV infection, only R5 HIV-1 detectable, and no antiretroviral therapy for 12 weeks 
[Thompson, 2009]. Placebo (n=10) and three PRO 140 doses were examined: 162 mg weekly for 
three weeks (n=11), 324 mg weekly for three weeks (n=11), and 324 mg biweekly (every other 
week) for two doses (n=12). Subjects were followed for 44 days after the final dose. 
Potent, dose-dependent and highly statistically significant antiviral activity was observed. The trial 
established the first antiviral proof of concept for a long-acting, self-administrable drug for HIV-1 
infection [Thompson, 2009]. 
Subcutaneous PRO 140 was generally well tolerated both locally and systemically. There was no 
obvious dose-related pattern of toxicity. The most common adverse events (diarrhea, headache, 
lymphadenopathy and hypertension) were mild to moderate and self-resolving. These events are 
common in HIV infection and were reported with similar frequencies in the placebo and PRO 140 
treatment groups. Administration-site reactions were mild, transient, and observed in a fraction of 
subjects. 
PRO 140_CD01 Study 
PRO 140_CD01 study (open-label, 43 subjects, multi-center) evaluated the efficacy, safety, and 
tolerability of PRO 140 monotherapy (350 mg subcutaneous injection weekly for up to 12 weeks) 
for the maintenance of viral suppression following substitution of antiretroviral therapy in HIV-1 
infected patients (with exclusive CCR5-tropic virus). Participants in this study were experienced 
HIV-infected individuals who were virologically suppressed on combination antiretroviral therapy. 
Consenting patients were shifted from combination antiretroviral regimen to PRO 140 monotherapy 
for 12 weeks. 
Forty-three (43) subjects (M/F: 37/3) with median age of 54.5 years (26-72) and median CD4 T- 
cell count of 604.5 cells/mm3 (365-1240) were enrolled in the CD01 study. Overall, twenty-two 
out of 40 (55%) enrolled subjects completed 12 weeks of PRO 140 monotherapy without 
experiencing virologic failure. Virologic failure was defined as two consecutive HIV-1 RNA levels 
of ≥ 400 copies/mL separated by at least 3 days. Of the 43 enrolled subjects, 3 subjects were found 
to have Dual/Mixed (D/M) tropism [1 at baseline and 2 at the time of virologic failure] and 37 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 28 of 96 
 
 
 
subjects were found to have exclusive CCR5-tropic virus. A letter of amendment was filed to 
increase the planned number of subjects from 40 to 43 subjects to compensate for the 3 Dual/Mixed 
subjects enrolled in the study. 
All virologic failure subjects who had available lab data in both studies achieved viral suppression 
to < 400 HIV-1 RNA copies/mL, as well as viral suppression to ‘Non Detectable’ or < 50 HIV-1 
RNA copies/mL after re-initiation of Antiretroviral Therapy (ART). 
The by-subject analysis of PhenoSense® Entry Assay data for PRO140, maraviroc, and AMD3100 
shows no significant changes in the post-treatment IC50 and IC90 values were noted when 
compared with baseline values in virologic failure and non-virologic failure groups of subjects. As 
the aggregate analysis shows for initial 40 subjects, the subjects who experienced virologic failure 
had higher IC90 value for PRO 140 at baseline compared to subjects without virologic failure. The 
mean IC90 for subjects who experienced virologic failure was higher (10.84 µg/mL) than the IC90 
for subjects without virologic failure (6.70 µg/mL) in the CD01 study (p=0.0115). 
Anti-PRO 140 antibodies were not identified in any post-treatment sample and data derived from 
the CD01 study further supports the favorable PRO 140 PK profile data generated from both pre- 
clinical as well as prior Phase 1/2 clinical trials. 
Safety data were analyzed for all 43 enrolled subjects. One (1) of 43 subjects experienced a Serious 
Adverse Event (SAE) that was deemed not related to the study drug by the Principal Investigator. 
Twenty-eight (28) of 43 subjects (67%) experienced one or more AEs after receiving at least one 
dose of PRO140. The most commonly occurring AEs were infections and infestation conditions 
which were reported by 14 of 43 (32.5%) subjects. The majority of the reported AEs (62/87; 71.2%) 
were deemed either unlikely or not related to study treatment by the Investigator. Similarly, the 
majority of the reported AEs (70/87; 80.4%) were deemed mild in nature. 
PRO 140_CD01 Extension Study 
PRO 140_CD01-Extension study (open-label, 28 subjects, multi-center) seeks to evaluate the 
efficacy, safety, and tolerability of PRO 140 monotherapy (350 mg subcutaneous injection weekly) 
for the continued maintenance of viral suppression following substitution of antiretroviral therapy 
in HIV patients (with exclusive CCR5-tropic virus). Participants in this study were HIV-infected 
individuals who were virologically suppressed on combination antiretroviral therapy and completed 
the first 12 weeks of CD01 study without experiencing virologic failure. As with the CD01 study, 
virologic failure was defined as two consecutive HIV-1 RNA levels of ≥ 400 copies/mL separated 
by at least 3 days. Consenting patients may remain on PRO 140 monotherapy until PRO 140 
receives marketing approval or Investigational New Drug (IND) application is withdrawn by 
Sponsor. 
A total of 17 subjects participated in the CD01-Extension study of which one subject was 
considered not eligible as subject experienced virologic failure prior to first extension treatment. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 29 of 96 
 
 
 
Sixteen (16) eligible subjects (M/F: 14/2) with median age of 54.9 years (26-68) and median CD4 
T-cell count of 593 cells/mm3 (365-1059) were enrolled in an extension study. One patient 
discontinued at week 37 (with viral load of <40 copies/mL) due to relocation. Two subjects were 
withdrawn due to non-treatment related SAEs at week 140 and 149, respectively. One subject was 
withdrawn due to re-starting their ART at week 99. Two subjects withdrew consent at week 81 and 
139, respectively. Five (5) subjects experienced virologic failure (VF) (two consecutive viral load 
of ≥400 copies/mL). The mean time to virologic failure was 329 days (106-691). 
Five (5) subjects are currently receiving weekly 350 mg PRO140 SC monotherapy and have 
completed more than three years of treatment (176 – 198 weeks). Overall, 12 subjects completed at 
least one year of treatment and 9 subjects completed at least two years of treatment in this study 
PRO140 was generally well tolerated, and no drug-related SAEs were observed. 
This clinical study is currently ongoing. 
PRO 140_CD02 Study 
PRO 140_CD02 study (double blind, placebo controlled, 52 subjects, multi-center) seeks to 
evaluate the efficacy, safety, and tolerability of PRO 140 in combination with either existing ART 
(failing regimen) or Optimized Background Therapy (OBT) in patients infected with HIV-1. The 
study population includes 52 adult patients with a documented history of genotypic or phenotypic 
resistance to ART drugs within two or more drug classes who demonstrate evidence of HIV-1 
replication despite ongoing antiretroviral therapy and have limited treatment options. The options 
may be limited as a result of drug antiviral class cross-resistance, documented treatment intolerance, 
documented objective assessments such as renal or hepatic insufficiency (e.g. high creatinine at 
baseline, limiting treatment options due to potential for toxicity), past adverse reactions such as 
hypersensitivity reactions or neuropsychiatric issues that could limit use of currently approved 
drugs. 
In Part 1 of double-blind treatment period, virally non-suppressed subjects will be randomized and 
treated with either PRO 140 or Placebo in combination with the failing ART regimen for 7 days 
until HIV-1 genotypic drug resistance assay results are available to construct an OBT. The primary 
efficacy endpoint is proportion of participants with ≥ 0.5 log10 reduction in HIV-1 RNA viral load 
from baseline at the end of the 7 day functional monotherapy period. 
In Part 2 of double-blind treatment period, subjects will continue treatment with PRO 140 in 
combination with OBT within the 24-week open-label period. 
Fifty-two subjects with a mean age of 52.4 years, 73.1% male, 48.1% non-white and mean duration 
of HIV-1 infection of 20.4 years were randomized 1:1 to the PRO 140 SC or placebo arm. Subjects 
had been previously exposed to an average of 11 ART drugs and had documented resistance to >9 
ART drugs. Mean baseline Viral Load (VL) and CD4 cell count were 21,104 c/mL and 297.8 
c/mm3, respectively. The primary efficacy endpoint- the proportion of patients with ≥0.5 log10 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 30 of 96 
 
 
 
reduction in HIV-1 VL from baseline at the end of the 1-week double-blind, randomized, placebo- 
controlled treatment period- was met (16/25 vs 6/26 [p-value <0.0032, ITT population]). Forty 
seven (47) of 52 patients have completed the 25-week study. Approximately 81% of patients 
completing 25-weeks of PRO 140 SC treatment demonstrated HIV-1 VL <50 c/mL and 92% had 
HIV-1 VL <400 c/mL. Continued access to PRO 140 SC was provided through a rollover study 
and 40 patients entered the extension protocol after completing the CD02 study. PRO 140 SC was 
generally well tolerated. No drug-related SAEs or treatment discontinuations were reported in the 
study. This clinical study is completed. 
PRO 140_CD06 Study 
PRO 140_CD06 study (double-blind, 80 subjects, single-center) seeks to evaluate the comparability 
of PRO 140 formulation Batch Lot # 3-FIN-3143 versus formulation Batch Lot# 3-FIN-2618 as a 
one-time subcutaneous (SC) injection in healthy subjects under non-fasting conditions. This clinical 
study is completed. 
PRO 140_CD02 Extension Study 
PRO 140_CD02 Extension study (open label, 40 subjects, multi-center) seeks to evaluate the long 
term efficacy, safety and tolerability of PRO 140 weekly injection in combination with Optimized 
Background Therapy (OBT) in patients infected with HIV-1. The study population includes 40 
treatment-experienced HIV-infected adult patients with CCR5-tropic virus who successfully 
completed PRO 140_CD02 study and continues to demonstrate HIV-1 viral suppression. 
This clinical study is currently ongoing. 
 
PRO 140_CD03 HIV Study 
PRO 140_CD03 HIV (open-label, 566 subjects, multi-center) is a three part study enrolling virally 
suppressed HIV-1 patients with CCR5-tropic HIV-1 receiving combination antiretroviral (cART) 
therapy. Patients received weekly doses of PRO 140 on single-agent maintenance therapy following 
one week of overlap of the existing cART regimen that is then discontinued. In part 1, 156 
participants received 350 mg PRO 140 SC in a single-arm design. In part 2, 147 participants 
received 350 or 525 mg PRO 140 SC in a 1:1 ratio as randomized controlled, two-arm study. In an 
ongoing part 3, 263 participants have been randomized to receive 525 or 700 mg PRO 140 SC in a 
1:1 ratio. 
Of the 566 patients enrolled, median age was 52 yrs (21-81) with the majority reported as male 
(78%) and 38% were non-white. A total of 132 subjects have been randomized to 700 mg dose. In 
addition, another 71 subjects have been exposed to 700mg dose after rescuing from the lower doses 
(350 mg or 525mg). On average, participants were diagnosed with HIV-1 infection for 
approximately 17 yrs and were on cART regimen for approximately15 yrs. The frequency and 
severity of injection site reactions were comparable between the three dose groups (350, 525 and 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 31 of 96 
 
 
 
700mg) and the incidence or severity of injection site reactions was not increased in patients 
receiving higher doses. Overall, PRO 140 SC was generally well tolerated at all dose levels in this 
study. 
This clinical study is currently ongoing. 
 
PRO 140_CD03 HIV Extension Study 
PRO 140_CD03 study (open-label, 350 subjects, multi-center) seeks to evaluate the long term 
efficacy, safety and tolerability of PRO 140 SC as long-acting single-agent maintenance therapy in 
virologically suppressed subjects with CCR5-tropic HIV-1 infection. The study population includes 
up to 300 treatment-experienced HIV-infected adult patients who successfully completed PRO 
140_CD03 HIV study and continue to demonstrate HIV-1 viral suppression. 
This clinical study is currently ongoing. 
 
CD07_TNBC Study 
CD07_TNBC study (open-label, two-part [Phase Ib: Up to 18 subjects; Phase II: 30 Subjects], 
multi-center) seeks to evaluate the efficacy, safety, tolerability and Maximum Tolerated Dose 
(MTD) of leronlimab (PRO 140) when combined with carboplatin in patients with CCR5+ 
metastatic triple-negative breast cancer (mTNBC). 
The study population includes patients with CCR5-positive, locally advanced or metastatic triple- 
negative breast cancer (mTNBC) who are naïve to chemotherapy in metastatic setting but have been 
exposed to anthracyclines and taxane in neoadjuvant and adjuvant settings (first-line). 
This clinical study is currently ongoing. 
 
CD08 mCRC Study 
CD08_mCRC study (open-label, 30 Subjects, multi-center) seeks to evaluate the effect on Overall 
Response Rate (ORR) of Leronlimab (PRO 140) when combined with Regorafenib in patients with 
CCR5+, Microsatellite Stable (MSS), Metastatic Colorectal Cancer (mCRC). 
The study population includes patients with CCR5+, MSS, mCRC who have been previously 
treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-Vascular 
Endothelial Growth Factor (VEGF) therapy, and, if RAS wild type, an anti- Epidermal Growth 
Factor Receptor (EGFR) therapy. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 35 of 96 
 
 
 
Leronlimab 700mg Exposure Summary in Clinical Trials 
 
 
Duration of 
Treatment 
Approximate Number of 
Subjects Received 700mg 
dose of Leronlimab 
CD10_COVID-19 
A Randomized, Double Blind, Placebo Controlled Study to 
Evaluate the Efficacy and Safety of Leronlimab for Mild to 
Moderate Coronavirus Disease 2019 (COVID-19) 
2 Weeks 
56 
CD12_COVID-19 
A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, 
Adaptive Design Study to Evaluate the Efficacy and Safety of 
Leronlimab for Patients with Severe or Critical Coronavirus 
Disease 2019 (COVID-19) 
2 Weeks 
130 
PRO 140_CD03 
A Multicenter Study to Assess the Clinical Safety and Treatment 
Strategy of Using PRO 140 SC as Long-Acting Single-Agent 
Maintenance Therapy for 48 Weeks in Virologically Suppressed 
Subjects with CCR5-tropic HIV-1 infection 
Up to 48 Weeks 
132 
+ 
79 (Rescue dose) 
PRO 140_CD03 extension 
An Extension Protocol for Virologically Suppressed Subjects 
Who Successfully Completed PRO140_CD03 Study 
Up to 100+ 
Weeks 
29 
Total Number of Subjects receiving Leronlimab 700mg dose: 
426 
The safety profile of Leronlimab (PRO 140) has been extensively evaluated in clinical trials of 
HIV-positive patients. Data accumulated for PRO 140 suggest a favorable profile in terms of safety 
in humans and efficacy against HIV-1 infection. PRO 140 has been administered intravenously or 
subcutaneously to more than 750 healthy and HIV-1 infected individuals in Phase I/II/III studies. 
The drug has been well tolerated following intravenous administration of single doses of 0.5 to 10 
mg/kg or up to 700 mg weekly doses as SC injection. Overall, more than 250 subjects have been 
exposed to PRO 140 525 mg SC weekly dose with the longest duration of exposure lasting >2 years. 
Similarly, more than 150 subjects have been exposed to PRO 140 700 mg SC weekly dose, 
respectively. To date, the longest exposure to PRO 140 700 mg SC weekly dose is 48 weeks. 
Subjects treated with 525 mg and 700 mg Leronlimab (PRO 140) have not experienced any SAEs 
related to Leronlimab (PRO 140). The majority of AEs have been mild in severity. In addition, 
there have been no presented patterns of drug-related toxicities observed during treatment with 525 
mg and 700 mg Leronlimab (PRO 140). The most common AEs have been injection site reactions, 
the majority which have been mild and considered as self-resolving. Considering the favorable 
safety profile of PRO 140 to date, this study is meant to further evaluate safety and potential efficacy 
of Leronlimab (PRO 140 at 700 mg) compared to placebo in adult patients with NASH. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 36 of 96 
 
 
 
We anticipate a manageable safety profile with Leronlimab (PRO 140) therapy since: 1) 
Leronlimab (PRO 140) is not metabolized by the liver, and therefore may have the potential for a 
better tolerability profile than many of the existing small-molecule therapies; 2) Unlike small 
molecules, monoclonal antibodies are too large to be filtered by the kidneys and are not eliminated 
in the urine, except in pathologic conditions. If low molecular weight antibody fragments are 
filtered, they are usually reabsorbed and metabolized in the proximal tubule of the nephron. 
Considering the results of studies on CCR5 blocker we believe, CCR5 inhibition may provide us 
with a new strategy for the treatment of NASH. 
 
1.7 
RISKS / BENEFITS ASSESSMENT 
 
Risks/Discomfort to Subjects and Precautions to Minimize Risk 
 
Allergic Reaction 
Leronlimab (PRO 140) belongs to the monoclonal antibody class of drugs. Monoclonal antibodies 
are sometimes associated with allergic reactions or flu-like reactions (such as fever, chills, and 
aches) or injection-site reactions. These events are usually of short duration if they occur at all. 
Severe allergic reactions, however, can be life-threatening. Although anaphylaxis has not been 
observed in prior trials of Leronlimab (PRO 140), infusion of proteins always carries with it the 
theoretical risk for anaphylactic shock. Accordingly, whenever Leronlimab (PRO 140) is 
administered to subjects, there should be available and in place the procedures required to manage 
anaphylactic shock. 
 
Immune Response 
People who take Leronlimab (PRO 140) or other monoclonal antibodies can also develop an 
immune response to Leronlimab (PRO 140) that may affect their ability to receive monoclonal 
antibodies, or to benefit from diagnosis or therapy with a monoclonal antibody in the future. 
 
Pregnancy 
Risks to unborn babies are unknown at this time; pregnant females will be excluded from this study. 
Females of childbearing potential must have a negative pregnancy test prior to enrollment. Both 
male and female patients and their partners of childbearing potential must agree to use appropriate 
birth control methods throughout the study duration (excluding women who are not of childbearing 
potential and men who have been sterilized). 
 
Venipuncture 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 37 of 96 
 
 
 
Blood sampling is required as part of the study protocol. Blood sampling carries a minimal risk of 
minor discomfort and the possibility of minor bruising at the site of the needle puncture and, 
rarely, the possibility of infection at the needle puncture site. 
 
Unknown Risks 
As with all research there is the remote possibility of risks that are unknown or that cannot be 
foreseen based on current information. 
 
Theoretical risk for increased severity of West Nile virus infection 
Individuals who lack a functional CCR5 gene are at increased risk for severe infection by West Nile 
virus [Thompson, 2009]. Because of this, treatment with CCR5 co-receptor antagonists poses a 
theoretical risk for increased severity of West Nile virus infection. However, this concern is 
mitigated by several factors. First, no increased risk was observed for individuals who possess one 
functional and one non-functional CCR5 gene, indicating that an intermediate amount of CCR5 is 
sufficient for defense against West Nile virus [Thompson, 2009]. Second, use of CCR5 co-receptor 
antagonists is unlikely to completely abrogate CCR5 function, and there has been no association 
reported to date between CCR5 co-receptor use and severe West Nile virus. Additionally, 
Leronlimab (PRO 140) weakly antagonizes the natural activity of CCR5 and thus is less likely to 
adversely affect immune function. However, patients enrolled in this study may have immune 
suppression from chemotherapy and therefore, the investigators will be alerted to risks of West Nile 
infections. Furthermore, this has not been established to be a risk with maraviroc, the other FDA- 
approved anti-CCR5 drug already. 
Collectively, the experience with both IV and SC, simulation modeling and the recent confirmation 
that a higher concentration of Leronlimab (PRO 140) synthesized using a highly efficient CHO cell 
line can be conveniently and safely administered has resulted in the design of the current study. 
Intended Benefit for Subjects 
This study provides an opportunity for subjects with NASH to have once weekly SC treatment with 
Leronlimab (PRO 140). Subjects participating in the present study will contribute to the 
development of a drug which has the potential to become a treatment option for them and others in 
the future. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 38 of 96 
 
 
 
2 
STUDY OBJECTIVES 
 
2.1 
PRIMARY OBJECTIVE: 
 The Primary objective of this study is to assess the efficacy of Leronlimab (PRO 140) in 
improving liver function in adult patients diagnosed with NASH compared to placebo 
 
2.2 
SECONDARY OBJECTIVE: 
 The Secondary objective of this study is to assess the safety and tolerability of 
Leronlimab (PRO 140) in adult patients diagnosed with NASH compared to placebo 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 39 of 96 
 
 
 
3 
STUDY DESIGN 
 
This is a phase II, multi-center, two-part study (Part 1: randomized, double-blind, placebo- 
controlled, two-arm with 60 patients; Part 2: non-randomized, single-arm, open-label with 30 
patients) designed to evaluate the safety and efficacy of leronlimab (PRO 140) SC in patients with 
NASH for 13 weeks. In Part 1 of the study, leronlimab (PRO 140 at 700 mg dose) or placebo will 
be weekly administered subcutaneously by a licensed healthcare professional at the clinic sites. 
A single arm, non-randomized, open-label phase (Part 2) is added to the protocol after completion 
of enrollment in the Randomized Phase (Part 1) of the study. In Part 2 of the study, leronlimab (PRO 
140 350 mg dose) will be weekly administered subcutaneously (SC) by a licensed healthcare 
professional at the clinic sites. 
 Part 1: randomized, double-blind, placebo-controlled, two-arm (up to 60 subjects) 
 Leronlimab (PRO 140 700 mg) or Placebo SC weekly injection for 13 weeks 
 Part 2: non-randomized, open-label, single-arm (up to 30 subjects) 
 Leronlimab (PRO 140 350 mg) SC weekly injection for 13 weeks 
This study consists of screening, treatment, and follow-up periods. 
The study flow diagram is presented in Figure 3-1. 
 
3.1 
STUDY CENTERS 
Up to 20 centers in the United States (US). 
 
3.2 
STUDY POPULATION 
For this study, adult patients with NASH will be enrolled. This will be a multicenter trial with up to 
90 subjects. 
Eligibility will be evaluated by the study team according to the following criteria. Eligibility waivers 
are not permitted. Subjects must meet all of the inclusion and none of the exclusion criteria to be 
enrolled in the study. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 40 of 96 
 
 
 
Figure 3-1: 
Study Design Schematic 
 
 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 41 of 96 
 
 
 
3.3 
ELIGIBILITY CRITERIA 
 
Inclusion Criteria 
Subjects are required to meet ALL of the following criteria for enrollment into the study: 
1. Subject is a male or female between 18 to 75 years of age inclusive. 
2. Evidence of nonalcoholic steatohepatitis (NASH) based on one of the following criteria: 
 Criteria 1: Histologically-confirmed diagnosis of NASH on a liver biopsy, or 
 Criteria 2: FibroScan or Shearwave US during screening (or within 6 months before 
screening) shows kPa ≥7 but <14 and CAP ≥260. 
3. Subject shows presence of hepatic fat fraction as defined by ≥ 8% on MRI-PDFF and cT1 
≥ 800 ms at Screening. 
4. Has had a stable body weight (±5%) within 6 months prior to Screening. 
5. Body Mass Index (BMI) ≥ 28 kg/m2 at Screening 
6. Has clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered 
not clinically significant by the Principal Investigator. 
7. Laboratory Screening results as indicated below: 
a. AST:ALT Ratio ≤ 1, if AST or ALT value is > ULN 
b. Screening Liver enzymes (AST, ALT, and ALK PHOS) < 5 x ULN. 
c. Total Bilirubin ≤ 1.3 mg/dL (except if Gilbert’s Disease) 
d. Platelet count ≥ 150,000/mm3 
e. International normalized ratio (INR) < 1.3 
f. Estimated Glomerular Filtration Rate (eGFR) ≥ 60/mL/min 
g. Glycosylated hemoglobin (HbA1c) < 9%. 
h. TSH within normal reference range. 
Note: Any subject with a non-clinically significant TSH value outside of the normal range 
may be enrolled if their T3 and free T4 values are within the normal range. 
8. Subjects with pre-diabetes or type 2 diabetes will be allowed to participate if the following 
criteria is met: 
 Subjects who are taking anti-diabetic medications should be on a stable dose for a period 
of at least 3 months prior to Screening and do not anticipate clinically significant dose 
adjustments during the course of study. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 42 of 96 
 
 
 
  Subjects must be on a stable diet/lifestyle regimen for at least 3 months prior to 
screening and do not anticipate a clinically significant change during the course of study. 
9. Subjects who are taking Vitamin E should be on a stable dose of Vitamin E (if ≥ 400 IU) 
for a period of at least 4 weeks prior to Screening and do not anticipate dose adjustments 
for the duration of the study. 
10. Both male and female patients and their partners of childbearing potential must agree to use 
two medically accepted methods of contraception (e.g., barrier contraceptives [male 
condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives 
[implants, injectables, combination oral contraceptives, transdermal patches, or 
contraceptive rings], or one of the following methods of birth control (intrauterine devices, 
tubal sterilization or vasectomy) or must practice complete abstinence from intercourse of 
reproductive potential from study entry to 6 months after the last day of treatment (excluding 
women who are not of childbearing potential and men who have been sterilized). 
11. Females of child-bearing potential must have a negative serum pregnancy test at Screening 
Visit and negative urine pregnancy test prior to receiving the first dose of study drug; and 
Male participants must agree to use contraception and refrain from donating sperm for at 
least 90 days after the last dose of study intervention. 
12. Subject is willing and able to give informed consent prior to any study specific procedures 
being performed. 
13. Subject is willing and able to comply with scheduled visits, drug administration plan, 
laboratory tests, other study procedures and study restrictions. 
 
 
Exclusion Criteria 
Subjects meeting ANY of the following criteria will be excluded from enrollment: 
1. Any concurrent clinically significant liver disease with an etiology other than NASH 
including autoimmune hepatitis, alcoholic hepatitis, hypoxic/ischemic hepatopathy, and 
biliary tract disease. 
2. History of alcohol consumption greater than 21/units/week (for males) and 14/units/week 
(for females) within the last 2 years prior to screening. 
Note: Use of online unit calculator for alcohol consumption is recommended (e.g., 
https://alcoholchange.org.uk/alcohol-facts/interactive-tools/unit-calculator) 
3. Any drug-induced steatohepatitis secondary to amiodarone, corticosteroids, estrogens, 
methotrexate, tetracycline, or other medications known to cause hepatic steatosis. 
4. Undergone major surgery, including liver surgery, within 6 months prior to screening. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 43 of 96 
 
 
 
5. Prior or pending liver transplantation. 
6. History or presence of cirrhosis or stage 4 fibrosis in historical liver biopsy and/or hepatic 
decompensation including ascites, hepatic encephalopathy or variceal bleeding. 
7. Active hepatitis B (defined as having a positive hepatitis B surface antigen [HBsAg] test), 
hepatitis C (defined as having a positive Anti-HCV test with detectable reflex HCV RNA; 
Note: Subject with positive Anti-HCV test and with undetectable HCV RNA would not be 
excluded), acute hepatitis A (defined as subjects with serum positive for hepatitis A IgM 
(HAV) antibody) or acute hepatitis E (defined as having anti-HEV IgM antibody). 
8. Any active infection requiring systemic therapy at the time of screening, which is considered 
clinically significant per the Investigator. 
9. Positive test for human immunodeficiency virus (HIV) or HIV infection. 
10. History of bleeding diathesis within 6 months of screening. 
11. Any malignancy within the past 5 years, excluding successfully treated basal cell carcinoma 
or squamous cell carcinoma without evidence of metastases. 
12. Seizure disorder requiring ongoing antiseizure therapy or with any condition that, in the 
judgment of the investigator, is likely to increase the risk of seizure (e.g. CNS malignancy) 
13. Clinically significant active cardiac disease which would interfere with study conduct or 
study results interpretation per the PI. 
14. Any known psychiatric or substance abuse disorders that would interfere with cooperation 
with the requirements of the trial. 
15. Prior therapy with Leronlimab or any other CCR5 antagonist (e.g. maraviroc) within 6 
months prior to screening. 
16. History of severe allergic, anaphylactic, or other hypersensitivity reactions to humanized 
monoclonal antibodies. 
17. Any condition requiring continuous systemic treatment with immunosuppressive (such as 
corticosteroids) or immunomodulatory medications. 
Note: Inhaled or topical steroids of up to 5 mg daily prednisone equivalent dose are 
permitted in the absence of active autoimmune disease. 
18. History of administration of a live, attenuated vaccine within four weeks prior to start of 
PRO 140 treatment or anticipation that such a live attenuated vaccine will be required during 
the remainder of the study. 
Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and 
are allowed; however intranasal influenza vaccines (e.g., Flu-Mist ®) are live attenuated 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 44 of 96 
 
 
 
vaccines, and are not allowed. 
19. Currently participating in an investigational study or received an investigational drug within 
28 days or 5 half-lives (whichever is longer) prior to study drug administration. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 46 of 96 
 
 
 
Subjects who complete the treatment period will continue to End of Treatment (EOT) Visit 
assessments at week 14 and enter the Follow-up Phase of the study. Subjects who meet any criteria 
for discontinuation of study treatment as specified in Section 5.1 of the protocol, will undergo Early 
Termination (ET) Visit assessments 7 days after the last injection and enter the Follow-up Phase of 
the study. 
Follow-Up Period: Follow-up visit will be conducted 28 (± 3) days after the End of Treatment 
(EOT) or Early Termination (ET) Visit. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 49 of 96 
 
 
 
Other: Fasting blood Glucose , Serum HbA1C, Thyroid profile 
Note: Screening laboratory testing can be repeated once during the 28-day screening window based on the Investigator’s clinical judgement). 
[12] 
Urine samples will be tested for pH, appearance, color, specific gravity, turbidity, ketones, bilirubin, occult blood, glucose, protein, nitrites, urobilinogen, and 
leukocyte esterases. Microscopic examination of urine sediment will be performed if there are abnormalities in macroscopic urinalysis results. Microscopic urine 
tests include bacteria, cast, crystals, epithelial cells, RBC and WBC. 
[13] 
Only performed on women of childbearing potential 
[14] 
Blood sample collected at T1 (prior to first dose of PRO 140), pre-dose at T2, T6, T10, and at EOT (or ET) and Follow-up visit 
[15] 
Randomization via WebView CTMS system only applicable for Part 1 of the study 
[16] 
Leronlimab (PRO 140) or placebo is administered as subcutaneous injection in the abdomen weekly. In Part 1 of the study, a total of 700 mg dose of leronlimab 
(PRO 140) or placebo will be delivered as two injections of 2 mL. In the Part 2 of the study, a total dose of 350 mg dose of leronlimab (PRO 140) will be 
delivered as one injection of 2 mL. 
[17] 
Injection Site Reaction Assessment as assessed by Investigator (or designee) at the clinic . 
[18] 
Subject-perceived injection site pain (average pain since last treatment) will be assessed using 11-point Numeric Rating Scale from 0 to 10 prior to each study 
treatment administration. “0” meaning “no pain” and “10” meaning “worst possible” pain. 
[19] 
AE and CM evaluations to be conducted at each clinic visit applicable 
[20] 
Subjects discontinuing the study at any time for any reason (early termination-ET) should complete the procedures listed AND the follow-up visit 
[21] 
In case subjects have already completed their EOT/ET and FU visits, site should use the Unscheduled Visit option to collect blood sample for Monocyte/T Cell 
CCR5 analysis. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 50 of 96 
 
 
 
4.1 
SCREENING PERIOD 
 
Screening Visit 
The subject will sign and date the Informed Consent Form (ICF) and Health Insurance Portability 
and Accountability Act (HIPAA) authorization (according to site policy and practices) prior to any 
study-related procedures. A unique identification number (screening number) will be assigned to 
each subject who has provided written informed consent. The screening number will incorporate a 
three-digit Study Center number (101, 102, etc.) and a three-digit numeric ID assigned in successive 
order of consenting to screening procedures after signing the ICF at each center, beginning with 001 
at each site (e.g. 101-001 or 102-001, etc.). 
 
XXX 
- 
YYY 
Subject Screening #: 
 
 
XXX=Study Center  
YYY=Subject Numeric ID 
 
All study centers will be instructed to maintain the study-specific screening and enrollment logs at 
their sites. If a subject initially fails to meet inclusion/exclusion criteria and is later reconsidered for 
participation, the subject will be re-consented and assigned a new screening number at the time of 
re-screening. Subjects who fail their first screening attempt may be re-screened a maximum of once 
and may be enrolled if they are found to meet all inclusion and no exclusion criteria when re- 
screened. 
Once the Screening ICF has been signed, screening procedures and information will be obtained to 
confirm subject eligibility including: 
 Demographic information and baseline disease characteristics (see Section 7.3), 
 Medical history (see Section 7.4), 
 Prior and concomitant medications assessment (see Section 7.5), 
 Vital Signs (see Section 7.6), 
 Body Weight & Height measurements (see Section 7.6), 
 Physical examination (see Section 7.7), 
 12-lead Electrocardiogram (see Section 7.8) 
 FibroScan (or equivalent non-invasive imaging test) (see Section 7.13) 
 Collection of lab specimens (see Section 7.9) for 
o Complete blood count 
o Biochemistry 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 51 of 96 
 
 
o Serum pregnancy test, for female subjects of childbearing potential 
o Urine sample for urinalysis parameters 
o FibroTest 
o HBS Ag, HCV Ab and HCV RNA (if required), HIV Ab, HAV IgM antibody, and 
HEV Ab 
 Liver MRI (see section 7.14) 
All screening information will be fully documented in the subject’s medical records (i.e., source 
documents). 
 For consented subjects who do not meet eligibility criteria, a Screen Failure Case Report 
Form (CRF) will be completed. The Screen Failure CRF will contain the following details: 
the subject identification number, the date of ICF signature, demographic information (see 
Section 7.3), and the reason for screen failure. No additional information will be required for 
subjects who fail screening. 
 For consented subjects who meet eligibility criteria, all required screening information will 
be transcribed onto the appropriate page of the CRF. 
 
4.2 
TREATMENT PERIOD 
Subjects who meet all eligibility criteria, as per data gathered from Screening Period are to be 
treated. All subjects who fail to meet eligibility criteria will be considered screen failure and exit 
the study without further evaluation 
The maximum sample size for this study is 90 subjects that will be followed by treatment according 
to the schedule described above. 
In Part 1 of the study, eligible subjects will be randomized to 1:1 to one of the two study arms to 
receive Leronlimab (PRO 140) 700 mg (Group A), or placebo (Group B) as two subcutaneous 
injections, given once per week (± 1 day) for up to 13 weeks during the treatment period. 
 PRO 140 700mg SC weekly injection (Group A) 
 Placebo 0 mg SC weekly injection (Group B) 
The study treatment (PRO 140 700 mg or placebo SC injections) will be administered by a licensed 
healthcare professional once a week at the study site. 
In Part 2 of the study, eligible subjects will be enrolled to receive leronlimab (PRO 140) 350 mg as 
one injection, given once per week (± 1 day) for up to 13 weeks during the treatment period. 
 PRO 140 350mg SC weekly injection 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 52 of 96 
 
 
The study treatment (PRO 140 350 mg SC injection) will be administered by a licensed healthcare 
professional once a week at the study site. 
Treatment Visit 1 (T1) 
The following assessments will be performed at the first treatment visit, unless otherwise specified: 
Pre-Treatment 
 Confirmation of eligibility criteria by reviewing test results and other criteria assessments 
performed at Screening Visit (see Section 7.2) 
 Vital Signs and body weight measurement (see Section 7.6), 
 Physical examination (see section 7.7), 
 12-lead Electrocardiogram (see Section 7.8) 
 Change in concomitant medications (see Section 7.5), 
 Any changes in medical history since Screening Visit (see Section 7.4), 
 Randomization only applicable for Part 1 of the study (see Section 8.4) 
 Collection of lab specimens (see Section 7.9) for 
o Complete blood count 
o Biochemistry 
o Urine pregnancy test, for female subjects of childbearing potential 
o Urine sample for urinalysis parameters 
o FibroTest 
o Anti-Drug Antibodies (ADA) to PRO 140 
o PK evaluations 
o Serum pro-inflammatory cytokine/chemokine evaluations 
o Monocyte/T cell CCR5 biomarker assay 
Administration of study treatment [PRO 140 or placebo] 
PRO 140 or placebo is administered as subcutaneous injection in the abdomen weekly. In part 1 of 
the study, a total of 700 mg (175 mg/mL) or placebo is delivered as two injections of 2 mL on 
opposite sides of the abdomen. In Part 2 of the study, a dose of 350 mg of leronlimab (PRO 140) 
(175 mg/mL) will be delivered as one injection of 2 mL and administered subcutaneously in the 
abdomen. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 53 of 96 
 
 
Note: All study treatments (PRO 140 or placebo) must be administered by a licensed healthcare 
professional. 
Post-Treatment 
 Injection Site Reaction Assessment (see Section 7.11) 
 Assessment of Adverse Events (AE) ( see Section 9.1) 
 Vital Signs (see Section 7.6) will be assessed within 15 minutes of study treatment 
administration. 
After treatment administration, subjects who meet any criteria for discontinuation of study 
treatment as specified in Section 5.1 of the protocol, will undergo End of Treatment (EOT) Visit 
assessments and enter the Follow-up Phase of the study. 
Treatment Visit 2 (T2) to Treatment Visit 13 (T13) 
The following assessments will be performed at each visit, unless otherwise specified: 
 Assess for any AEs (see Section 9.1) 
 Concomitant medications assessment (see Section 7.5) 
 Vital Signs and body weight measurement (see Section 7.6) (weight only on visits T2, T6, 
T10 ) 
 Symptom-directed physical examination at clinic visits (see Section 7.7) (only on visits T2, 
T6, T10) 
 12-lead Electrocardiogram (see Section 7.8) (only on visits T2, T6, T10) 
 Collection of lab specimens at T2 , T6, T10 (see Section 7.9 ) for: 
o Complete blood count 
o Biochemistry 
o Urine sample for urinalysis parameters 
o Urine pregnancy test, for female subjects of childbearing potential (T6 and T10 
only) 
o FibroTest 
o Anti-Drug Antibodies (ADA) to PRO 140 
o PK assessment 
o Serum pro-inflammatory cytokine/chemokine evaluations 
o Monocyte/T cell CCR5 biomarker assay 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 54 of 96 
 
 
 Leronlimab (PRO 140) Administration (see Section 6.4) 
 Injection Site Reaction Assessment (see Section 7.11) 
 Subject-perceived Injection Site Pain Assessment (see Section 7.12) 
Note: Subject-perceived injection site pain will be assessed using 11-point Numeric Pain Rating 
Scale from 0 to 10 prior to study treatment administration assessing average pain at injection site 
since last treatment. “0” meaning “no pain” and “10” meaning “worst possible pain”. 
End of Treatment (EOT) Visit 
Subjects who complete the treatment period will undergo End of Treatment (EOT) Visit. The 
following assessments will be performed for the subjects: 
 Assess for any Adverse Events (see Section 9.1) 
 Changes in Concomitant medications (see Section 7.5), 
 Physical examination (see Section 7.7), 
 Vital Signs and body weight measurement (see Section 7.6), 
 Subject-perceived Injection Site Pain Assessment (see Section 7.12), 
 12-lead Electrocardiogram (see section 7.8), 
 Liver MRI (see section 7.14) 
 Collection of Blood Specimens (see section 0) for: 
o Complete Blood Count 
o Biochemistry 
o FibroTest 
o Anti-Drug Antibodies (ADA) to PRO 140 
o PK assessment 
o Serum pro-inflammatory cytokine/chemokine evaluations 
o Monocyte/T cell CCR5 biomarker assay 
Note: In case subjects have already completed their EOT/ET and FU visits, site should 
use the Unscheduled Visit option to collect blood sample for Monocyte/T Cell CCR5 
analysis. 
 
 Urine pregnancy test, for female subjects of childbearing potential. 
 Urine sample for urinalysis parameters 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 55 of 96 
 
 
Early Termination (ET) Visit 
Subjects who meet any criteria for discontinuation of study treatment as specified in Section 5.1 of 
the protocol, will undergo Early Termination (ET) Visit. 
The following assessments will be performed: 
 Assess for any Adverse Events (see Section 9.1) 
 Changes in Concomitant medications (see Section 7.5), 
 Symptom-directed physical examination (see Section 7.7), 
 Vital Signs and body weight measurement (see Section 7.6), 
 12-lead Electrocardiogram (see section 7.8), 
 Liver MRI (see section 7.14) 
 Collection of Blood Specimens (see section 0) for: 
o Complete Blood Count 
o Biochemistry 
o FibroTest 
o Anti-Drug Antibodies (ADA) to PRO 140 
o PK assessment 
o Serum pro-inflammatory cytokine/chemokine evaluations 
o Monocyte/T cell CCR5 biomarker assay 
 Urine pregnancy test, for female subjects of childbearing potential. 
 Urine sample for urinalysis parameters 
 
4.3 
FOLLOW-UP PERIOD 
Follow- up visit will be conducted 28 (± 3) days after the End of Treatment (EOT) or Early 
Termination (ET) Visit. All subjects will be followed for biochemistry lab assessment, anti-drug 
antibodies (ADA) to PRO 140, PK assessment, serum pro-inflammatory assessment, blood sample 
for Monocyte/T cell CCR5 biomarker assay vital signs, symptom-directed physical exam, adverse 
events, and concomitant medications assessment. 
Subjects who discontinue treatment for unacceptable adverse event(s) will be followed until 
resolution or stabilization of the adverse event (i.e. the grade is not changing). 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 56 of 96 
 
 
4.4 
UNSCHEDULED VISITS 
In the event that the subject will return to clinic at a time other than a regularly scheduled study 
visit, the visit will be regarded as an unscheduled visit. Assessments at unscheduled visits are at 
the discretion of the Investigator. All pertinent findings, including adverse events or changes in 
medications, will be noted in the eCRF. 
Any hospitalization or ER visits in between the scheduled visits should be promptly notified to the 
site staff. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 57 of 96 
 
 
5 SUBJECT COMPLETION, WITHDRAWAL AND CRITERIA FOR 
STOPPING THE STUDY 
A subject who has completed the 14-week treatment period and 4-week follow-up period will be 
considered as having completed the study. 
 
5.1 
SUBJECT WITHDRAWAL 
A subject who enters the Treatment Phase but does not complete the study, as defined in this section, 
is considered to have prematurely withdrawn (early terminated) from the Study. 
All subjects have the right to withdraw at any point during treatment without prejudice to future 
care. It will be documented whether or not each subject completed the clinical study. If for any 
subject, study treatment or observations were discontinued, the reason(s) will be recorded. 
Subjects WILL be withdrawn from the study, in consultation with the Medical Monitor and the 
Investigator, if any of the following are met: 
 A subject is significantly non-compliant with the requirements of the protocol. 
 The Investigator determines that it is in the best interest of the subject. 
 Subject chooses to withdraw or is withdrawn due to an adverse event 
 A subject becomes pregnant 
Note: The pregnancy will be followed to term for safety follow-up. Relevant safety information 
collected after the study has completed will be reported as supplemental information. 
 Discontinuation of study by Sponsor 
 Subject becomes lost to follow-up (LTF) 
 Subject experiences unacceptable toxicity 
 Subject voluntarily withdraws from treatment (follow-up permitted) 
 Subject withdraws consent (no follow-up permitted) 
Discontinuation of study treatment for the individual subject MAY occur if, in consultation with the 
Medical Monitor and the Investigator, any of the following are met: 
 A subject is treated with a prohibited medication. 
 Diabetic subjects with an increased HbA1C results of >9% or experiencing significant 
changes in glucose control requiring modification to the dosage or regimen of antidiabetic 
medication 
 Major protocol violation (Section 0) 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 58 of 96 
 
 
 Subjects who have two occurrences of a Grade 2 or higher allergic/hypersensitivity reaction 
directly related to the study drug that lead to permanent discontinuation of study drug. 
 Subjects experiencing grade 3 or higher AE (per CTCAE v5.0) that is possibly or probably 
related to the study drug OR grade 4 or higher AE regardless of attribution to the study drug. 
 Subjects considered to potentially have Drug-Induced Liver Injury (DILI) as described 
below. 
Drug- induced liver Injury (DILI) 
If subjects with abnormal baseline liver indices develop elevations of AST or ALT >2x baseline or 
Total Bilirubin (TBL) >1.5x baseline values during the study, the tests will be repeated within 48- 
72 hours. If there are persistent elevations (AST or ALT>2x baseline or TBL >1.5 baseline values) 
upon repeat testing, then close observation of the subjects per below should be implemented and 
discontinuation of the study treatment will be considered as per Section 5.1. During the close 
observation period, liver enzyme and serum bilirubin tests will need to be repeated two or three times 
weekly. Frequency of retesting can decrease to once a week or less if abnormalities stabilize or the 
study treatment has been discontinued and the subject is asymptomatic. 
Additionally, further gastroenterology or hepatology consultations and/or liver biopsy can be 
considered per Investigator’s discretion. 
If patient is unable to come to clinic for blood draw during the close observation period, laboratory 
testing can be performed locally, and the results should be promptly communicated to the 
investigator site. A decision to discontinue or temporarily interrupt the study drug will be considered 
based on factors that include how much higher than baseline the ALT and AST are relative to the 
upper limit of normal (ULN) and how much the AST and ALT levels have increased relative to 
baseline, in addition to whether there is a concomitant elevation of bilirubin or INR. The study 
treatment will be discontinued or temporarily interrupted under the following conditions: 
 If Baseline Measurements (BLM) were <2x ULN, The study treatment should be 
discontinued if ALT or AST increases to >5x BLM 
 If BLM was 2x ULN but <5x ULN, The study treatment will be discontinued if ALT or AST 
increases to 3x BLM 
 If BLM was 5x ULN, The study treatment will be discontinued if ALT or AST increases to 
>2x BLM 
 If ALT or AST increases >2x BLM and the increase is accompanied by a concomitant 
increase in TB to >2x BLM or the INR concomitantly increases by 0.2, The study treatment 
will be discontinued 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 59 of 96 
 
 
 If any subject presents with signs or symptoms of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and or eosinophilia (>5%), the study treatment 
should be discontinued 
Note: For the purpose of the assessment of drug-induced liver injury (DILI), Baseline Measurements 
(BLM) for lab values (such as AST, ALT, total Bilirubin) refers to the average (mean) value of 
Screening Visit (SV) and T1 Visit. If liver function tests are repeated during Screening Phase, the 
average (mean) value of all Screening Visit tests and T1 Visit will be used to calculate the Baseline 
Measurements. 
All data normally collected at the scheduled EOT Visit should be recorded at the time of premature 
discontinuation. 
If a subject fails to return for the scheduled study visit or is discontinued from the study, an attempt 
will be made to determine the reason(s). If the subject is unreachable by telephone, a registered 
letter will be sent to the subject requesting that he/she contact the clinic. 
All patients with an ongoing SAE at the Post-Study (Follow-up) Visit (scheduled or premature) 
must be followed until the event is resolved (with or without sequelae) or deemed stable. 
 
5.2 
SUBJECT REPLACEMENT 
Subject replacement is not applicable in this study. 
 
5.3 
DATA COLLECTED FROM WITHDRAWN SUBJECTS 
Every attempt should be made to collect follow-up information. The reason for withdrawal from 
the study will be recorded in the source documents and on the appropriate page of the CRF. 
Before a subject is identified as lost-to-follow up, the site should make all reasonable efforts to 
contact the subject. These attempts must be documented and should include at a minimum one 
phone call and one certified letter. 
In the event that a subject is withdrawn from the study at any time due to an adverse event or SAE, 
the procedures stated in Sections 9.2 and 9.4 must be followed. 
 
5.4 
SCREEN FAILURES 
A subject who signed a consent form, but did not meet the inclusion/exclusion criteria is classified 
as a screen failure. Subject number, demographics and reason for screen failure will be recorded. 
In the event that a subject initially fails to meet inclusion/exclusion criteria and is later reconsidered 
for participation, will be re-consented and assigned a new screening number at the time of re- 
screening. Subjects who fail their first screening attempt may be re-screened again (i.e., up to two 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 60 of 96 
 
 
screenings) and may be enrolled if they are found to meet all inclusion and no exclusion criteria at 
the subsequent screening visit. 
 
5.5 
CLINICAL TRIAL STOPPING CRITERIA 
The clinical trial should be halted if any of the following occurs: 
 Three patients develop the same Grade 3 AE attributed to the study drug per CTCAE v5.0 
OR 
 Two patients develop any Grade 4 AE attributed to study drug per CTCAE v5.0 
OR 
 One patient develops a grade 5 AE attributed to study drug per CTCAE v5.0 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 63 of 96 
 
 
Protocol: CDI-NASH-01 
Site No.  
 
Kit No. N01-XXXX 
Subject No.  
 
Kit contains 2 single-use vials of PRO 140 2mL at 175 mg/mL solution for 
subcutaneous injection 
USE AS PER STUDY PROTOCOL 
Store at 2oC to 8oC 
Caution: New Drug – Limited by Federal (or United States) Law to 
Investigational Use 
CytoDyn Inc., Vancouver, WA, USA 
Below are representative samples of the Investigational Product, FDP individual vial (Figure 6-1), 
and kit label ( 
Figure 6-2) designated for use in this clinical protocol. Each kit contains two labeled vials. 
Figure 6-1: 
Investigational Product - Vial Label 
 
 
Protocol: CDI-NASH-01 
Kit No. N01-XXXX 
Subject No.  
 
Single use vial of PRO 140 2 mL at 175 mg/mL solution for 
subcutaneous injection 
Store at 2oC to 8oC 
Caution: New Drug – Limited by Federal (or United States) 
Law to Investigational Use 
CytoDyn Inc., Vancouver, WA, USA 
Protocol: CDI-NASH-01 
Kit No. N01-XXXX 
Subject No.  
 
Single use vial of PRO 140 2 mL at 175 mg/mL solution for 
subcutaneous injection 
Store at 2oC to 8oC 
Caution: New Drug – Limited by Federal (or United States) 
Law to Investigational Use 
CytoDyn Inc., Vancouver, WA, USA 
 
Figure 6-2: 
Investigational Product - Kit Label 
 
 
The pharmacy manual provides the criteria regarding vial acceptance or rejection, as well as 
instructions for the preparation of the IP syringes to be used to administer drug. 
 
6.3 
LERONLIMAB (PRO 140) - STORAGE AND HANDLING 
Study drug will be shipped at 2°C to 8°C (refrigerated [36°F to 46°F]) to the investigator’s site. 
Upon receipt at the site, the responsible site staff or pharmacist should verify the integrity of the 
vials. Study drug should be stored at 2°C to 8°C (refrigerated [36°F to 46°F]). The contents of the 
vial should appear as a clear to opalescent, colorless to yellow solution; fine translucent particles 
may be present. This is normal. 
The investigator must maintain an accurate record of the shipment, storage, and dispensing of the 
study drug in a drug accountability log. An accurate record including the date and amount of study 
drug dispensed to each subject must be available for inspection at any time. An unblinded study 
Clinical Research Associate (CRA) assigned to monitor the investigational site will review these 
documents once study drug has been received by the investigational site. Study drug will be 
accounted for on an ongoing basis during the study. 
 
6.4 
INVESTIGATIONAL PRODUCT ADMINISTRATION 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 64 of 96 
 
 
Guidelines for dose preparation can be found in the pharmacy manual. 
Leronlimab (PRO 140) will be provided to the administering personnel in single-use syringes 
prepared from vials of study drug stored at 2-8°C at the site pharmacy prior to use. In Part 1 of the 
study, each of two syringes is filled to deliver 2.0 mL of study drug. Equivalent volumes of PRO 
140 or placebo will be administered subcutaneously on opposite sides of the abdomen. 
In Part 2 of the study, one syringe is filled to deliver 2.0 mL of study drug. Leronlimab (PRO 140) 
will be administered subcutaneously in the abdomen. 
A 20-guage needle should be used to remove PRO 140 or placebo from vial and a 25-guage needle 
is used for administration to subjects. 
Note: After the leronlimab or placebo solution is drawn into the syringe, it can be stored at 
 room temperature (20°C to 25°C, 68°F to 77°F) for up to 2 hours, or 
 refrigerated (2°C to 8°C, 36°F to 46°F) for up to 4 hours. 
IP should be administered slowly over 15 seconds per mL. 
Following each SC delivery of drug, careful examination will be made to assess the appearance of 
any study drug Injection Site Reactions (ISRs) as per CTCAE v5.0. 
In Part 1 of the study, all doses of study drug will be prepared by either the unblinded credentialed 
pharmacist or qualified medical professional and will be provided to a blinded licensed healthcare 
professional at clinic site to be administered as SC injection. The blinding aspect is not applicable 
for the Part 2 of the study. 
All Leronlimab (PRO 140) SC weekly injections must be administered at clinic by a healthcare 
professional. 
Note: It is preferred that the same injection site be used throughout the study. At the same time, it 
is not recommended to inject the study drug into areas where skin shows signs of a previous 
injection site reaction. It is advised to change the injection site if any previous injection site reaction 
remains unresolved. 
Post Injection Monitoring 
Subject will be observed at approximately 30 minutes post-injection or longer, if necessary, for 
injection site reaction as per CTCAE v5.0. 
In addition, the tolerability of repeated subcutaneous administration of PRO 140 is evaluated based 
on assessment of subject-perceived injection site pain using 11-point Numeric Pain Rating Scale. 
Dose Modifications 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 66 of 96 
 
 
7 
DESCRIPTION OF PROTOCOL ASSESSMENTS AND PROCEDURES 
 
7.1 
INFORMED CONSENT 
A written informed consent will be obtained for this study for pre-screening and screening by the 
Investigator or designee from all subjects prior to performance of any protocol-specific procedure. 
This study will be conducted in accordance with the provisions of the Declaration of Helsinki. 
The Investigator must comply with applicable regulatory requirements and must adhere to the GCP 
in the process of obtaining and documenting the informed consent. The Investigator, or designee, 
must also inform subjects of all pertinent aspects of the study. Before written informed consent is 
obtained from the subject, the Investigator or a person designated by the Investigator, must provide 
the subject enough time and opportunity to inquire about the details of the study and to decide 
whether or not to participate in the trial. All questions addressed by the subject about the study must 
be answered to the satisfaction of the subject. Prior to the subject’s participation in the trial, the 
written informed consent must be signed and personally dated by the subject and by the person who 
conducted the informed consent discussion. Authorization for release of protected health 
information must also be obtained, as per local policies. 
 
7.2 
ASSESSMENT OF ELIGIBILITY 
The Investigator must assess subject’ continued eligibility for the study as per the Inclusion and 
Exclusion criteria, during the Screening Period. The eligibility criteria are described in Section 0 
(Inclusion Criteria) and Section 0 (Exclusion Criteria). In the event that the subject is not suitable 
or eligible for the study, the subject will be considered “screen failure”. 
Re-screening 
If a subject fails initially to meet the eligibility criteria, and is later reconsidered for participation, 
the subject will be re-consented and assigned a new screening number at the time of re-screening. 
Subjects who fail their first screening attempt may be re-screened a maximum of once and may be 
enrolled in the study only if they meet all Inclusion and no Exclusion criteria when re-screened. 
 
7.3 
DEMOGRAPHIC INFORMATION AND BASELINE DISEASE CHARACTERISTICS 
In this study the demographic information will include: 
 Dates of ICF signature 
 Date of birth 
 Gender 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 67 of 96 
 
 
 Race (American Indian/Alaskan Native, Asian, Black/African American, Native 
Hawaiian/Pacific Islander, Caucasian, or other) 
 Ethnicity (Hispanic/Latino or Not Hispanic/Latino) 
In addition, the following baseline disease characteristics will be collected: 
 Disease diagnosis date 
 
Medications used for the indication 
 Previous histological procedures, if available for the indication: 
o Date of the most recent procedure 
o Stage of liver fibrosis per the most recent procedure 
o Any indication for cirrhosis per the most recent procedure 
o Stage of steatosis per the most recent procedure 
 
7.4 
MEDICAL HISTORY 
A complete review of the subject’s past medical history (including prior and concurrent liver 
disease and cirrhosis), past surgeries, current therapies (medications and non-medications), and 
history of exposure to environmental chemical agents will be undertaken by the Investigator to 
check that all inclusion and no exclusion criteria have been met. 
Events that emerge prior to the first treatment (T1) will be recorded in the medical history and not 
as AEs. Aside from being used to determine subject eligibility, this information will permit the 
Investigator to record the nature, duration and severity of any ongoing baseline medical conditions 
prior to the subject’s receiving investigational product treatment. 
Medical histories will be recorded using the body system categories outlined below: 
 
 Cardiovascular 
 Lymphatic 
 Respiratory 
 Hematologic 
 Gastrointestinal 
 Immunologic 
 Renal 
 Dermatologic 
 Hepatic 
 Psychiatric 
 Neurological 
 Genitourinary 
 Endocrine 
 Other 
 
For each relevant history, the following will be documented: 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 68 of 96 
 
 
 Disease/disorder/condition 
 Date of diagnosis 
 History status (resolved or ongoing). 
 
7.5 
CONCOMITANT MEDICATION 
All concomitant medication administered or taken by the subject beginning 6 month prior to 
Screening Visit and throughout the study will be recorded in the source documents and on the 
appropriate page of the Case Report Form (CRF) including all prescription, over-the-counter 
(OTC), herbal supplements, and IV medications and fluids. If changes occur during the trial period, 
documentation of drug dosage, frequency, route, and date may also be included on the CRF. 
Subjects must be questioned at each study visit concerning any new medications or changes in 
current medications including over-the-counter medication and topical medication. 
For each medication and non-study treatment, the following will be documented: 
 Medication/treatment name (generic name may be used if trade name is unknown) 
 Dose, unit, and frequency of dosing (individual dosages, not total daily dose). 
Note: Each new dose of medication should be recorded as a separate entry, with the exception of 
medications that are given on a sliding scale. For these, it is acceptable to enter the range of the 
dosage, including the start and stop dates for which the specified dosage range was used. 
 Route of dosing 
 Indication for use 
 The start date 
 The stop dates (if medication/therapy is not ongoing). 
Permitted Medications 
All treatments that the investigator considers necessary for a subject’s welfare may be administered 
at the discretion of the investigator in keeping with the community standards of medical care. 
Prohibited Medications 
Subjects are prohibited from receiving the following therapies during the Screening and Treatment 
Period of this trial: 
 Use of radiation or cytotoxic chemotherapy, immunosuppressants and immunomodulating 
agents (e.g., interleukins, interferons) 
 Use of any non-FDA approved/investigational therapy 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 69 of 96 
 
 
 Use of hepatotoxic medications such as antiarrhythmic drugs e.g., Amiodarone, Dronedarone 
 Clinically significant dose adjustments of the existing T2DM medication regimen or 
initiation of new anti-diabetic medications for the duration of the study. 
 
7.6 
VITAL SIGNS, HEIGHT AND WEIGHT 
The following will be collected: 
 Vital signs: 
o Seated blood pressure (taken after the subject has been seated for at least 5 minutes) 
o Pulse 
o Temperature (oral or tympanic) 
o Respiratory Rate 
 Height (only at the Screening Visit) 
 Weight 
 BMI (derived from the height and weight measurements). 
 
7.7 
PHYSICAL EXAMINATION 
The physical examination will include routine examinations for the following: 
 Head, Ears, Eyes, Nose, Throat (HEENT) 
 Abnormalities of the extremities 
 Neurologic abnormalities 
 Heart/cardiovascular abnormalities 
 Musculoskeletal abnormalities 
 Dermatologic abnormalities 
 Any other body system for which an abnormality is noted and which, in the opinion of the 
Investigator, is relevant to the safety of the subject or could impact safety or efficacy results 
for the subject; i.e., the abnormality is clinically significant. 
Each abnormality will be recorded and the Investigator will record an assessment of its clinical 
significance. 
The complete physical examination will be conducted at the Screening Visit (SV), T1 (Pre- 
treatment) and End of Treatment (EOT) Visit. Only symptom-directed physical examination will 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 70 of 96 
 
 
be performed at treatment visits T2, T6, T10 and at unscheduled visits within the Treatment period 
and also at Early Termination (ET) Visit and Follow-up Visit. 
 
7.8 
ELECTROCARDIOGRAM (ECG) 
A resting supine 12-lead ECG will be conducted at Screening Visit (SV), T1 (Pre-treatment), T2, 
T6, T10, EOT/ET visits. A 12-lead ECG will be repeated during the study only if clinically 
indicated and at the discretion of the treating physician. The results will be evaluated by the 
Investigator. The following parameters will be recorded: ventricular rate (beats per minute), PR 
interval (msec), QRS interval (msec), QT interval (msec), and QTc interval (msec). Additionally, 
the Investigator will record the overall results of the ECG reading as either normal or abnormal, 
and as either not clinically significant or clinically significant. If abnormalities are observed, each 
will be recorded. 
 
7.9 
CLINICAL LABORATORY ASSESSMENTS 
Blood samples will be collected for analysis of the following parameters: 
 Hematology (Complete Blood Count) will be performed at SV, T1 (prior to first dose), T2, 
T6, T10, EOT/ET visits. 
 Biochemistry will be performed at SV, T1 (prior to first dose), T2, T6, T10, EOT/ET and 
FU visits. 
Note: Screening laboratory test can be repeated once during the 28-day screening window 
based on the Investigator’s clinical judgement). 
 Serum pro-inflammatory biomarkers including IL-1 alpha, IL-1 beta, IL-6, RANTES 
(CCL5), TNF-alpha, TNF-beta, CRP will be performed at T1 (prior to first dose), T2 (pre- 
dose), T6 (pre-dose), T10 (pre-dose), EOT/ET and FU visits. 
 FibroTest (requires fasting for 12 hours or more) combines 5 standard biomarkers (gamma- 
glutamyltransferase, total bilirubin, alpha-2-macroglobulin, apolipoprotein A1, and 
haptoglobin). The Acti-Test adds a marker for inflammatory activity (alanine 
aminotransferase: ALT). FibroTest will be performed at SV, T1 (prior to first dose), T2, 
T6, T10, EOT/ET visits. 
 Serology tests including HBs Ag, HCV Ab and HCV RNA (only performed if HCV Ab is 
positive), HIV Ab, Hepatitis A and Hepatitis E Abs will be performed at SV. 
 Anti-Drug antibodies (ADA) to PRO 140 at T1 (prior to first dose), T2 (pre-dose), T6 (pre- 
dose), T10 (pre-dose), EOT/ET and FU visits. 
 PK assessment at T1 (prior to first dose), T2 (pre-dose), T6 (pre-dose), T10 (pre-dose), 
EOT/ET and FU visits. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 71 of 96 
 
 
 Serum pregnancy test (for female subjects of childbearing potential) at SV. 
 Monocyte/T cell CCR5 biomarker assay at T1 (prior to first dose), T2 (pre-dose), T6 (pre- 
dose), T10 (pre-dose), EOT/ET and FU visits. 
Note: In case subjects have already completed their EOT/ET and FU visits, site should use 
the Unscheduled Visit option to collect blood sample for Monocyte/T Cell CCR5 analysis. 
 
Urine samples will be collected for analysis of the following parameters: 
 Urine pregnancy at T1 (prior to first dose), T6, T10, EOT/ET visits. 
Note: A urine sample will be collected from female subjects of childbearing potential. This 
test will be performed at the study site using a commercially available kit. 
 Urine analysis testing at SV, T1 (prior to first dose), T2, T6, T10, EOT/ET visits. 
Urine samples will be tested for color, appearance, specific gravity, pH, protein, glucose, occult 
blood, ketones, leukocyte esterases, nitrites, bilirubin, urobilinogen. Microscopic examination of 
urine sediment will be performed if there are abnormalities in macroscopic urinalysis results. 
Microscopic urine tests include bacteria, cast, crystals, epithelial cells, RBC and WBC. 
All laboratory reports will be reviewed by the Investigator. Abnormal results that are considered by 
the Investigator to be clinically significant will be recorded as adverse events. In order to make the 
determination of clinical significance the testing may be needed to be repeated as per Investigator’s 
judgement. Validated, quality-controlled laboratory data will be transferred to the main database 
for analyses. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 73 of 96 
 
 
 
Total Bilirubin 
0.2-0.9 mg/dl 
Direct Bilirubin 
0.0 – 0.2 mg/dl 
SGOT (AST) 
15-41 IU/L 
SGPT (ALT) 
M: 17-63 IU/L; F: 14-54 IU/L 
Alkaline Phosphatase (ALP) 
34-104 IU/L 
 
Sample Collection Guidelines 
Please refer to laboratory manual for more details 
 
Sample Processing, Storage, and Shipment 
Please refer to laboratory manual for more details 
 
7.10 STUDY TREATMENT APPLICATION 
Refer to Section 0 for details. 
 
7.11 POST-INJECTION EVALUATION AND INJECTION SITE REACTION ASSESSMENT 
At each treatment visit, an injection site reaction assessment will be made for the current and 
previous injection sites. Injection site reaction assessments are recorded by the Investigator starting 
after the first injection is given. Subject will be observed at approximately 30 minutes post-injection 
or longer if necessary for injection site reaction as per CTCAE v5.0. Refer to Sections 0 for more 
details. 
 
7.12 PAIN SEVERITY ASSESSMENT 
Tolerability of repeated subcutaneous administration of Leronlimab (PRO 140) is evaluated based 
on assessment of subject-perceived injection site pain using 11-point Numeric Pain Rating Scale. 
Before each study treatment administration (T2 to T13, and at EOT), subjects will be asked to 
evaluate the pain intensity over the past week at the site of injection administration based on 11- 
point Numeric Rating Scale from 0 to 10. “0” meaning “no pain” and “10” meaning “worst possible 
pain”. 
Figure 7-1: 
11-Point Numeric Pain Rating Scale 
 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 74 of 96 
 
 
7.13 FIBROSCAN 
Fibroscan ultrasound measures both liver fibrosis (scarring) and steatosis (fatty change). FibroScan 
steatosis (Controlled Attenuation Parameter (CAP)) score and fibrosis score will be evaluated for 
eligibility in this study. 
 
7.14 LIVER MRI (MULTISCAN) 
Liver MRI (MultiScan) is a non-invasive diagnostic technology for evaluating liver diseases using 
multiparametric MRI to non-invasively quantify liver tissue. Combining the information from 
multiple parametric maps provides a comprehensive analysis of liver tissue, which can be used to 
aid the diagnosis of liver disorders. 
The Magnetic Resonance Imaging–derived Proton Density Fat Fraction (MRI-PDFF) is a novel 
imaging-based biomarker that allows fat mapping of the entire liver. 
Corrected T1 (cT1) is also an MRI-based diagnostic imaging biomarker of the liver. cT1 is intended 
to be used as a proxy for inflammation and fibrosis. 
In this study, Liver MRI will be performed to evaluate MRI-derived biomarkers such as PDFF and 
cT1 at SV and EOT/ET visits. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 75 of 96 
 
 
8 
STATISTICAL ANALYSIS 
 
This section presents general information about statistical considerations and concepts and a brief 
discussion on analysis methodology, as well as some data conventions. Detailed descriptions of the 
statistical analysis methods and data conventions that will be used in this study will be in a separate 
document; i.e., the Statistical Analysis Plan (SAP). 
 
8.1 
TREATMENT GROUPS 
 
In Part 1 of the study, all eligible subjects will be randomized to receive PRO 140 as a 700mg 
subcutaneous injection or placebo weekly for up to 13 weeks. 
In Part 2 of the study, all eligible subjects will receive PRO 140 as a 350 mg subcutaneous injection 
weekly for up to 13 weeks. 
 
8.2 
STUDY OUTCOME MEASURES 
 
Primary Efficacy Outcome Measure: 
 Change from baseline in hepatic fat fraction assessed by magnetic resonance imaging- 
derived proton density fat fraction (MRI-PDFF) at week 14 
 Secondary Efficacy Outcome Measures: 
 Change from baseline in fibro-inflammatory activity as assessed by cT1 (corrected T1) 
assessed by multiparametric magnetic resonance imaging (MRI) of liver at week 14 
Note: cT1 measured in milliseconds (ms) is a quantitative metric for assessing a composite 
of liver inflammation and fibrosis 
 Change from baseline in liver fibrosis using FibroTest at week 14 
 Change from baseline in hepatic inflammatory activity using FibroTest at week 14 
 Change from baseline in serum pro-inflammatory biomarkers assessments 
 Change from baseline in Gamma-glutamyltransferase (GGT) at week 14 
 Change from baseline in CK-18 level at week 14 
 Change from baseline in Leronlimab (PRO 140) PK assessments 
Exploratory Outcome Measures: 
 Change from baseline in Alanine transaminase (ALT) at week 14 
 Change from baseline in Aspartate transaminase (AST) at week 14 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 76 of 96 
 
 
 Change from baseline in total bilirubin at week 14 
 Change from baseline in triglycerides at week 14 
 Change from baseline in Low Density Lipoprotein (LDL) at week 14 
 To explore Monocyte/T cell CCR5 biomarkers that may predict activity of leronlimab. 
 
8.3 
SAMPLE SIZE DETERMINATION AND RATIONALE 
 
The sample size of 90 total subjects [60 subjects (30 subjects per arm) for the Randomized Phase 
and up to 30 subjects for the non-randomized, open-label phase] is selected on the basis of clinical 
judgment and not based on statistical power calculation. The number of subjects is deemed adequate 
to provide clinically meaningful descriptive results consistent with study objectives. 
 
8.4 
RANDOMIZATION 
Subjects who are eligible to participate in the trial will be randomized to one of the treatment groups 
via IWRS (Interactive Web Based Randomization System) at the T1 Visit prior to IP administration. 
The randomization will be central and will use 1:1 ratio of Treatment groups A and B: 
 PRO 140 700mg SC weekly injection (Group A) 
 Placebo 0 mg SC weekly injection (Group B) 
Note: Randomization is not applicable for the open-label, single-arm portion (Part 2) of the study. 
 
8.5 
BLINDING 
All subjects, Investigators and their staff, and all Sponsor/CRO personnel involved in the 
management of the study will be blinded to treatment assignments. 
The 
Information Technology department will be unblinded to treatment. As noted above, 
the 
 Technology department is not otherwise involved with the study. 
Treatment unblinding for the study will occur after all clinical data have been received, data 
inconsistencies have been resolved, and the database is locked, except for safety reasons on a case- 
by-case basis (i.e., emergency unblinding). 
Note: Blinding is not applicable for the open-label, single-arm portion (Part 2) of the study. 
 
8.6 
INTERIM ANALYSIS 
No interim analysis (IA) will be performed for efficacy. 
 
8.7 
GENERAL STATISTICAL CONSIDERATIONS 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 77 of 96 
 
 
All collected study data will be presented in subject data listings. Statistical analyses will be 
performed using SAS® for Windows, version 9.4 or later. Descriptive statistics (n, mean, standard 
deviation, median, minimum and maximum) will be presented by treatment group for continuous 
variables. Frequencies and percentages will be presented by treatment group for categorical 
variables. 
Analysis Populations 
Intent-to-Treat Population 
The Intent-to-Treat (ITT) population is defined as the set of subjects who have received at least 
one dose of study treatment (Leronlimab (PRO 140) or placebo) and have at least one post-baseline 
efficacy assessment. The ITT population will be used as the primary analysis population. 
Per Protocol Population 
The Per Protocol (PP) population is defined as the set of subjects who meet the ITT population 
requirements, were not associated with any major protocol violations and have at least 80% of 
compliance with study treatment. This population will be identified before the database lock. 
The PP analysis of primary and secondary endpoints will be considered supportive. 
 
Safety Population 
The Safety Population will include all subjects who have received one dose of study treatment 
(Leronlimab (PRO 140) or placebo). This population will be used for the analysis of safety 
parameters. 
Covariates 
For efficacy analyses, the baseline values will be used as covariates in the analysis models. Other 
important prognostic factors will be specified in the SAP for the study. 
Missing Data 
All data will be used as observed, and no imputations will be made for any missing data point for 
early phase study. 
 
8.8 
ANALYSIS METHODS 
A SAP will be developed and approved before the database is locked. The SAP will present the 
detailed statistical methodology to be used in analyzing the data from this trial. All inferential 
statistical analysis will be based on a two-sided test with a Type I error rate of 0.05. 
All the efficacy analyses presented here will be conducted using both the ITT and PP populations. 
All safety analyses will be conducted using the Safety population. Continuous data summaries will 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 78 of 96 
 
 
include number of observations, mean, standard deviation, median, and minimum and maximum 
values. Categorical data summaries will include frequency counts and percentages. 
Subject Disposition 
The disposition of all subjects who sign an ICF will be provided. The numbers of subjects screened, 
randomized, received treatment, completed, and discontinued during the study, as well as the 
reasons for all post-enrollment discontinuations will be listed and/or summarized by treatment 
group. 
Demographic and Baseline Disease Characteristics 
Demographics and baseline disease characteristics including medical history, prior and concomitant 
medications/therapies will be listed and/or summarized by treatment group using appropriate 
descriptive statistics. 
Study Analyses 
Efficacy Analysis 
Analysis of the efficacy endpoints will be conducted according to below methods: 
o If the Normality assumption is met, Analysis of Covariance (ANCOVA) or Mixed 
Model using the covariates in the model. 
o If the Normality assumption is not met, a non-parametric method or a rank – 
ANCOVA analysis will be used. 
Safety Analyses 
Safety will be assessed by close monitoring and timely assessment of adverse events (AEs), 
laboratory parameters (blood tests, urinalysis), vital signs (blood pressure, heart rate), subject’s 
medical condition (physical examination including weight). Tolerability of repeated subcutaneous 
administration of Leronlimab (PRO 140) as assessed by study participants (using 11-point Numeric 
Pain Rating Scale) and by investigator-evaluation of injection site reactions. 
 
Adverse Events 
Adverse events will be coded using the most recent version of Medical Dictionary for Regulatory 
Activities (MedDRA). Treatment Emergent AE’s (TEAE) are defined as events with an onset on 
or after the first treatment. TEAEs will be summarized by treatment group, System Organ Class, 
and preferred term. The following TEAE summaries will be provided: 
 by PT in descending order of frequency 
 by SOC and PT 
 by SOC, PT, and severity 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 79 of 96 
 
 
 by SOC, PT, and relationship to study drug 
 
Clinical Laboratory Data 
All laboratory values will be listed. Laboratory measurements will also be summarized as 
continuous variable and presented by treatment group and time point. 
 
Physical Examination 
All physical examination findings will be listed and/or summarized. 
 
Vital Signs 
All vital sign findings will be listed and summarized. 
Electrocardiograms (ECGs) 
All ECG findings will be listed and summarized. 
Tolerability 
Pain severity assessment (using 11-point Numeric Pain Rating Scale) and injection site reactions 
will be listed and summarized. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 80 of 96 
 
 
9 ADVERSE EVENTS (DEFINITIONS AND REPORTING) 
 
The Investigator is responsible for the detection and documentation of events meeting the criteria 
and definition of an AE or SAE, as provided in this protocol. During the study when there is a safety 
evaluation, the Investigator or site staff will be responsible for detecting, documenting and reporting 
AEs and SAEs as detailed in this Section of the protocol. 
 
9.1 
ADVERSE EVENT (AE) 
An adverse event (AE) is defined as any unfavorable or unintended sign, symptom, or disease that 
occurs or is reported by the subject to have occurred, or a worsening of a pre-existing condition. 
An adverse event may or may not be related to the study treatment. 
AEs will be elicited through direct questioning and subject reports. Any abnormalities in visit 
evaluations, physical examination findings or laboratory results that the investigator believes are 
clinically significant to the research subject and that occurred after initiation of the first study 
treatment will be reported as AEs. Abnormal findings that are NOT clinically significant should be 
not be recorded as an AE. 
 
9.2 
REPORTING AND FOLLOW-UP OF ADVERSE EVENTS 
Report initiation for all AEs and serious adverse events (SAEs), (see Section 9.3), will begin at the 
time of the first treatment and continue up to the final study visit. All events will be followed to 
resolution or until 30 days after the subject completes the study. A final assessment of outcome will 
be made at that time. 
All AEs must be recorded in the subject’s medical records and on the CRF. AEs will be reported 
using customary medical terminology along with the following information: the onset and end 
dates, whether the event is considered to be a SAE (see Section 9.3), the impact the event had on 
study treatment (see Section 0), the CTCAE grade (intensity) of the event (see Section 0), the 
causality of the event (see Section 0), whether treatment was given as a result of the event (see 
Section 0), and the outcome of the event (see Section 0). 
Impact on Study Treatment 
The impact the event had on the study treatment will be assessed as either: dose increased, dose not 
changed, dose reduced, drug interrupted, drug withdrawn, unknown, and not applicable. The “not 
applicable” assessment will be used only when the subject is no longer in the treatment period of 
the protocol or died. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 82 of 96 
 
 
4. Probably – The event follows a reasonable temporal sequence from the study biologic or 
control, abates upon discontinuation of the study drug or control, or cannot be reasonably 
explained by known characteristics of the patient’s clinical state. 
5. Definitely – The event follows a reasonable temporal sequence from the study biologic or 
control, abates upon discontinuation and cannot be explained by known characteristics of 
the patient’s clinical state. 
Treatment Given as a Result of the Event 
The event impact in terms of treatment provided will be as either: none, medication administered, 
non-drug therapy administered, surgery performed, hospitalization, or other (with a specification). 
Outcome Assessment 
The outcome of the event will be assessed as either: fatal, not recovered/not resolved, 
recovered/resolved, recovered/resolved with sequalae, recovering/resolving, and unknown. Only 
one AE per subject is allowed to have an outcome assessment as “death.” If there are multiple 
causes of death for a given subject, only the primary cause of death will have an outcome of death 
Injection-site reactions 
Injection-site reactions thought to be directly related to the injection are considered to be AEs of 
special interest, and will be assessed as per CTCAE v5.0. 
For subjects who develop Grade 1 or Grade 2 events, therapy will be continued as per protocol. If 
a subject chooses to discontinue study treatment, the site should notify the protocol team leadership, 
and encourage the subject to complete any remaining study visits until the toxicity resolves. 
For subjects who develop Grade 3 events following study drug injection, the subject should be 
reevaluated closely until the AE returns to Grade 1 or less, at which time study treatment may be 
reintroduced at the discretion of the site investigator. If the same Grade 3 AE recurs following the 
next administration of study drug, study treatment must be permanently discontinued. Subjects 
experiencing Grade 3 AEs requiring permanent discontinuation of study treatment should be 
followed closely for resolution of the AE to Grade 1 or less and the team leadership must be notified. 
For Grade 4 events permanently discontinue therapy. 
 
9.3 
SERIOUS ADVERSE EVENTS 
A SAE is defined as any AE that: 
 Results in death 
 Is life threatening (the subject is at immediate risk of dying from the adverse experience) 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 83 of 96 
 
 
 Requires subject hospitalization or prolongs existing hospitalization 
 Results in persistent or significant disability/incapacity 
 Is a congenital anomaly/birth defect 
 Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered a serious adverse device effect when, based upon appropriate 
medical judgment, they may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition 
 
9.4 
REPORTING OF SERIOUS ADVERSE EVENTS 
The Investigator is required to report all SAEs that occur during the time period specified in 
Section 9.2. Once the Investigator becomes aware of an SAE, he/she must report the SAE to 
 Safety and Pharmacovigilance Department within 24 hours: 
 
 
 
 
A written SAE report must include a full description of the event as described in Section 9.2 and 
must follow within 24 hours from the time the Investigator first learned of the event. The
 
Medical Monitor may request additional supporting documentation as it becomes available, such 
as lab reports, electrocardiogram (ECG) reports, discharge summary, hospital notes, etc, if 
applicable. 
The Investigator is also responsible for reporting all SAEs to the appropriate Institutional Review 
Board (IRB) in accordance with local laws and regulations. The Investigator is responsible for 
maintaining documentation in the study file that indicates the IRB has been properly notified. 
 
9.5 
SAE FOLLOW-UP 
All subjects experiencing an SAE, including the discontinued subjects, must be closely followed 
until sufficient information is obtained to indicate a return to normal status or until the event 
stabilizes at a level acceptable to the investigator (i.e., recovery, return to baseline status, no further 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 84 of 96 
 
 
improvement expected, or death). 
For each SAE indicated as an unresolved event on the initial report, regardless of whether the 
subject completed the study or withdrew, the site should submit a follow-up report with updated 
information. 
9.5.1. Regulatory Reporting Requirements for SAEs 
The investigator, or responsible person per local requirements, must comply with the applicable local 
regulatory requirements related to the reports of SAEs to regulatory authorities and the Institutional 
Review Board (IRB)/ Institutional Ethics Committee (IEC). 
The Sponsor is responsible for the ongoing evaluation of the study drug. Any adverse experience 
associated with the use of the study drug that is both serious and unexpected must be reported. In 
accordance with the US Code of Federal Regulations, Title 21 CFR Part 312.32, and the ICH 
Guidelines for Clinical Safety Data Management Definitions and Standards for Expedited Reporting, 
the Sponsor must submit written documentation in the form of an Investigational New Drug (IND) 
Safety Report or suspected unexpected serious adverse reaction (SUSAR) reports, respectively. All 
events qualifying as IND Safety Reports/SUSARs will be reported to the IRB/IECs, and 
Investigators will be provided by the drug safety group for regulatory authorities. IND Safety 
Reports/SUSARs are required to be reported within 7 calendar days for life-threatening events and 
those resulting in death or 15 calendar days for all others. These timeframes begin with the first 
notification of the IND Safety Reports/SUSARs to the drug safety group from the Investigator. 
The Sponsor should submit to the regulatory authority all safety updates and periodic reports, as 
required by applicable regulatory requirements. 
 
9.6 
PREGNANCY REPORTING 
Pregnancies detected during the study must be reported to Medical Monitor within the same 
timelines as an SAE using the appropriate form. The outcome of a pregnancy should be followed up 
carefully and any abnormal outcome of the mother and/or child should be reported. The investigator 
must report any pregnancy that occurs in a study subject. Any female subject who becomes pregnant 
during the study will be discontinued from investigational product and will be followed for 
pregnancy outcome. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 85 of 96 
 
 
10 DIRECT ACCESS TO SOURCE DATA/DOCUMENTATION 
 
Subjects will be identified on eCRFs by a unique subject identification number and on source 
documents by name and date of birth. No personal identifier will be used in any publication or 
communication used to support this research study. The subject identification number will be used 
if it becomes necessary to identify data specific to a single subject. 
The local IRB, FDA, the monitors, auditors and personnel authorized by the Sponsor are eligible to 
review the medical and research records related to this study as part of their responsibility to protect 
human subjects in clinical research. They will be given direct access to source data and 
documentation (e.g., medical charts/records, printouts etc.) for source data verification, provided 
that subject confidentiality is maintained in accordance with local requirements. Access to 
electronic medical records may be governed by institution policy and each site will be required to 
ensure access while remaining compliant with institutional requirements. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 86 of 96 
 
 
11 QUALITY CONTROL AND QUALITY ASSURANCE 
 
11.1 MONITORING REQUIREMENTS 
The specific obligations outlined in 21 Code of Federal Regulations (CFR) and ICH guidelines 
require the Sponsor to maintain current personal knowledge of the progress of a study. Therefore, 
the Sponsor's designated monitor will visit the site during the study as well as maintain frequent 
telephone and written communication. The Investigator will permit the Sponsor to monitor the 
study as frequently as is deemed necessary and provide access to medical records to ensure that 
data are being recorded adequately, that data are verifiable and that protocol adherence is 
satisfactory. 
As delineated above, the Investigator will permit representatives of the Sponsor and/or designated 
CRO to inspect all CRFs and corresponding study subject original medical records (source 
documents) at regular intervals throughout the study. Subject original medical records and other 
relevant data must be available to support all data recorded in the eCRF. In addition to the original 
medical records, these data may include but are not limited to study, laboratory reports, etc. 
In accordance with federal regulations, site inspections will serve to verify strict adherence to the 
protocol and the accuracy of the data that is being entered on the case report forms. A Monitoring 
Log will be maintained at each study site. The Monitoring Log will be signed by the monitor, dated 
and stated the type of visit. The Investigator should be aware that the study site and subject records 
may be inspected by the Sponsor and or representatives of the designated CRO, FDA or other 
regional regulatory authority. 
 
11.2 ACCEPTABILITY OF CASE REPORT FORMS (CRFS) 
For each subject who has signed an informed consent form, a CRF must be completed. For subjects 
who are screen failures, this would be limited to the screen failure CRF page. All source documents 
and CRFs will be completed as soon as possible after the subject's visit and corrections to data on 
the CRFs will be documented, if applicable. The Investigator will review the CRFs to indicate that, 
to his/her knowledge, they are complete and accurate. CRFs will be reviewed by the Sponsor’s or 
designated CRO’s monitor, who will make a decision as to their acceptability. 
 
11.3 MODIFICATION OF PROTOCOL 
The Investigator will not modify or alter this protocol without first obtaining the concurrence of the 
Sponsor. Approval by the Investigator’s IRB must also be obtained prior to implementation of the 
change, with two exceptions: 
1. When necessary to eliminate apparent immediate hazard to the subject; or 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 87 of 96 
 
 
2. When the modification does not involve the subject’s participation in the trial. 
An amendment may also require modification of the informed consent form. The Investigator will 
provide an approval letter for the amendment and revised informed consent form, if applicable, to 
the Sponsor. An amendment must be provided in writing and it must be dated by both the Sponsor 
and the Investigator. If necessary, the Sponsor will submit protocol amendments to FDA and other 
appropriate regulatory authorities and notify other Investigators using this protocol. 
 
11.4 REPORTING PROTOCOL DEVIATIONS 
The Investigator is obligated to follow the protocol without departure from the requirements written 
in the protocol. If the Investigator deviates from the protocol requirements, the Sponsor will make 
the determination as to whether the subject will continue in the study. The Sponsor also has the 
right to discontinue the subject for protocol violations. The IRB may also have to be contacted if 
safety to the subject or if the scientific soundness of the study is involved. All protocol deviations 
must be documented in the CRFs. 
Major Protocol Deviation or Violation 
A major protocol deviation or violation is a deviation from the IRB approved protocol that may 
affect the subject's rights, safety, or well being and/or the completeness, accuracy and reliability of 
the study data. Examples of this include: 
 Failure to obtain informed consent prior to initiation of study-related procedures 
 A research subject does not meet the protocol's eligibility criteria but was enrolled without 
prior approval from the sponsor. 
 A research subject received the wrong treatment or incorrect dose. 
 A research subject met withdrawal criteria during the study but was not withdrawn. 
 A research subject received a prohibited concomitant medication. 
 Failure to treat research subjects per protocol procedures that specifically relate to primary 
efficacy outcomes. 
 Changing the protocol without prior sponsor and IRB approval. 
 Multiple minor violations of the same nature after multiple warnings. 
 Minor Protocol Deviation or Violation 
A minor protocol deviation is any change, divergence, or departure from the study design or 
procedures of a research protocol that has not been approved by the IRB and which DOES NOT 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 88 of 96 
 
 
have a major impact on the subject's rights, safety or well-being, or the completeness, accuracy and 
reliability of the study data. Examples of this include: 
 Follow-up visits that occurred outside the protocol required time frame because of the 
participant’s schedule. 
 Blood samples obtained at times close to but not precisely at the time points specified in the 
protocol. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 89 of 96 
 
 
12 ETHICS AND REGULATORY REQUIREMENTS 
 
This study is to be conducted in accordance with the specifications of this protocol and in 
accordance with principles consistent with Declaration of Helsinki, GCP, 21 CFR, ICH E6, HIPAA 
regulations in 45 CFR Part 164 (US only), and the Belmont Principles of respect for persons, 
beneficence, and justice. No protocol changes will be implemented without the prior review and 
approval of the IRB, except when the modification does not involve the subject’s participation in 
the trial or where it may be necessary to eliminate an immediate hazard to a research subject. In the 
latter case, the change will be reported to the IRB as soon as possible, according to IRB regulations. 
Additionally, the study product used in this study is manufactured, handled and stored in accordance 
with applicable GMP. The study product provided for this study will be used only in accordance 
with this protocol. 
 
12.1 INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC) 
The Principal Investigator (PI) at the site will provide the Institutional Review Board/Independent 
Ethics Committee (IRB/IEC) with all appropriate materials as required by their IRB/IEC, including 
but not limited to the clinical study protocol, informed consent form, and any advertising materials. 
The study will not be initiated until the IRB/IEC provides written approval of the aforementioned 
documents and until approval documents have been obtained by the Principal Investigator and 
Sponsor or Sponsor designee. The Investigator will not participate in the decision. If the 
Investigator is an IRB or IEC member, documentation must be provided indicating recusal from 
the approval process. Appropriate reports on the progress of this study by the Principal Investigator 
will be made to the IRB/IEC as required by local and applicable government regulations and in 
agreement with policy established by the Sponsor. The Investigator is required to maintain an 
accurate and complete record of all written correspondence to and received from the IRB/IEC, and 
must agree to share all such documents and reports with the Sponsor. 
No changes from the final approved protocol will be initiated without the IRB/IEC’s prior written 
approval or favorable opinion of a written amendment, except when necessary to eliminate 
immediate hazards to the subjects or when the modification does not involve the subject’s 
participation in the trial. 
 
12.2 INVESTIGATOR’S RESPONSIBILITIES 
The Investigators are responsible for performing the study in full accordance with the protocol and 
the current revision of the Declaration of Helsinki, the Good Clinical Practice: Consolidated 
Guideline, approved by the ICH, and any applicable national and local laws and regulations. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 90 of 96 
 
 
Information regarding to the study center participating in this study that cannot comply with these 
standards will be documented. 
 
12.3 SUBJECT INFORMED CONSENT REQUIREMENTS 
All subjects participating in this study will be given to by the Investigator and/or designee, written 
and oral information about the study in a language understandable by the subject. Written informed 
consent will be obtained from each subject prior any procedures or assessments that would not 
otherwise be required for the care of the subject are done and after the aims, methods, anticipated 
benefits, potential hazards, and insurance arrangements in force are explained and the subject has 
been given sufficient time to ask questions and consider participation in the study. It will also be 
explained to the subjects that they are free to refuse entry into the study and free to withdraw from 
the study at any time without prejudice to future treatment. It is permissible for a third person (e.g., 
a family member) to be present during the explanation of the study. 
The written Informed Consent Form ICF will be in compliance with CFR 21 Part 50.27 and GCP 
guidelines. The Sponsor and/or designated CRO will approve the ICF and all amendments to the 
ICF prior to submission to the IRB/IEC. A copy of the ICF to be used will be submitted by the 
Investigator to the IRB/IEC for review and approval prior to the start of the study. The study site 
must provide the Sponsor with an unsigned copy of IRB/IEC-approved ICF along with applicable 
documentation to support this approval. The original signed ICF is retained in the subject's study 
records, and a copy is provided to the subject. A second copy may be filed in the subject’s medical 
record, if allowed by institutional policy. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 91 of 96 
 
 
13 DATA HANDLING AND RECORD KEEPING 
 
13.1 RECORDING AND COLLECTION OF DATA 
The primary source document for this study will be the subject's medical record. If separate research 
records are maintained by the Investigator(s), the medical record and the research records will be 
considered the source documents for the purposes of auditing the study. 
Applicable source data will be manually transcribed to approve case report forms (CRF). The 
Investigator is ultimately responsible for the accuracy of the data transcribed on the forms. All 
source documents and CRFs will be completed as soon as possible after the subject's visit. 
The Investigator will review the CRFs to indicate that, to his/her knowledge, they are complete and 
accurate. Designated source documents will be signed and dated by the appropriate study personnel. 
The Investigator must agree to complete and maintain source documents and CRFs for each subject 
participating in the study. 
All research data will be entered, either electronically or manually, into a computerized database. 
The clinical database will be designed by the clinical data manager in accordance with 21 CFR Part 
11 and based on protocol requirements defined by the Sponsor in association with the Lead 
Investigator. 
The Investigator will maintain a confidential list of study subjects that will include each subject’s 
study number, name, date of birth, and unique hospital identification number if applicable. This list 
will be kept by the Investigator and will not be collected by the Sponsor. A notation will be made 
in the subject’s case history/medical chart that he/she is participating in a clinical study and has 
provided a signed and dated ICF as well as a release for protected health information as required 
by local policies. The Investigator must also maintain a separate screening log of all the subjects 
screened for participation in the study; it should include gender, age, eligibility status, reason for 
ineligibility, if applicable; and study allocated subject number, if applicable. 
 
13.2 CLINICAL DATA MANAGEMENT 
The Sponsor and/or designated CRO will be responsible for the processing and quality control of 
the data. Data management will be carried out as described in the Sponsor’s or CRO’s standard 
operating procedures (SOPs) for clinical studies. 
The handling of data, including data quality control, will comply with regulatory guidelines 
(e.g., ICH E6 GCP, and local regulations where applicable) and the Sponsor’s or the CRO’s SOPs 
as well as provisions of the study-specific Data Management Plan. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 92 of 96 
 
 
13.3 ARCHIVING 
All study documentation at the Investigator site and Sponsor site will be archived in accordance 
with ICH GCP E6 and the Sponsor’s quality standards and SOPs. 
The Investigator will maintain all research records, reports, and case history reports for a period of 
two (2) years after regulatory approval of the investigational product. If no application is filed or if 
the application is not approved, records must be maintained for two (2) years after all investigations 
have been completed, terminated or discontinued and the FDA has been notified. 
These documents should be retained for a longer period however, if required by the applicable 
regulatory requirements or if needed by Sponsor or its authorized representative (as per 
GCP 5.5.11). 
At the completion of the study, details of the archival process must be provided to the Sponsor. 
Study records are subject to inspection by applicable health and regulatory agencies at any time. 
Records to be retained by the Investigator include, but are not restricted to: 
 Source data and the primary records upon which they are based (e.g., subject’s progress 
notes, adverse event data, test results, and any other diagnostic procedures required to 
evaluate the progress of the study) 
 Completed CRFs 
 Signed protocols and protocol amendments 
 Laboratory results, ranges, and certifications 
 IP and accountability records 
 Study personnel signature log 
 Monitoring logs 
 Correspondence to and from the Sponsor, designee and IRB 
 Investigator and sub-investigator CVs 
 Signed informed consent and protected health information consent forms 
 Subject screening 
 SAE reports 
 IRB approval and re-approval letters 
 Other documents pertaining to the conduct of the study 
These documents must be maintained and kept on file by the Investigator so that the conduct of the 
study can be fully documented and monitored. 
Study records should not be transferred from site or destroyed without prior written agreement 
between the Sponsor and the study Investigator. Study records are subject to inspection by 
applicable health and regulatory agencies at any time. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 93 of 96 
 
 
14 PUBLICATION PLAN 
 
All information supplied by CytoDyn in connection with this study and not previously published, 
is considered confidential information. This information includes, but is not limited to, the 
Investigator’s Brochure, clinical protocol, case report forms and other scientific data. Any data 
collected during the study are also considered confidential. This confidential information shall 
remain the sole property of CytoDyn, shall not be disclosed to others without the written consent 
of CytoDyn, and shall not be used except in the performance of this study. 
It is understood by the Investigator that the Sponsor will use the information collected in this clinical 
trial in connection with the development of CytoDyn. Therefore, this information may be disclosed 
as required to other Investigators or appropriate regulatory authorities. By agreeing to participate 
in this clinical trial, the Investigator understands that he/she has an obligation to provide the Sponsor 
with complete test results and all data developed during this trial. 
Publication and Disclosure: The site and Investigator agree to submit any proposed manuscript, 
presentation or other public disclosure regarding the study to Sponsor for review at least thirty (30) 
days prior to submitting such proposed manuscript to a publisher or delivering or making such 
presentation or other public disclosure to any third party. Within thirty (30) days of its receipt, 
Sponsor shall advise the site and/or Investigator, as the case may be, in writing of any information 
contained therein that is confidential information (other than research results included in a proposed 
manuscript) or that may impair Sponsor’s ability to obtain patent protection. Sponsor shall have the 
right to require the site and/or Investigator, as applicable, to remove specifically identified 
confidential information (but may not require removal of research results from a proposed 
manuscript) and/or to delay the proposed submission or delivery of the proposed manuscript or 
presentation, or other public disclosure, for an additional sixty (60) days to enable Sponsor to seek 
patent protection. The site and Investigator shall not publish, publicly disclose, present or discuss 
any results of or information pertaining to the site’s and Investigator’s activities prior to completion 
of the trial, even if the multi-center trial or the study is terminated before its completion and the 
final clinical study report is signed off, or with respect to any endpoints or analyses other than those 
specified in this protocol. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 94 of 96 
 
 
15 REFERENCES 
 
Cichoż-Lach, H., Celiński, K., Prozorow-Król, B., Swatek, J., Słomka, M., & Lach, T. (2012). The 
BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in 
nonalcoholic fatty liver disease. Med Sci Monit, 18(12), CR735–CR740. 
Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, 
Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD. Antiviral activity of single-dose PRO 140, a 
CCR5 monoclonal antibody, in HIV-infected adults. Journal of Infectious Diseases. 2008 Nov 
1;198(9):1345-52. 
 
Jack X. Q. Pang. Liver Stiffness by Transient Elastography Predicts Liver-Related Complications 
and Mortality in Patients with Chronic Liver Disease. PLoS One, 2014; 9(4). 
Manca Povsic, L. O. A structured literature review of interventions used in the management of 
nonalcoholic steatohepatitis (NASH). Pharmacol Res Perspect, 2019; 7(3), e00485. 
Naga Chalasani, Z. Y. The Diagnosis and Management of Nonalcoholic Fatty Liver 
Disease:Practice Guidance From the American Association for the Study of Liver Diseases. 
HEPATOLOGY, 2018; 67(1) 
Lefebvre E, M. G. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in 
Animal Models of Liver and Kidney Fibrosis. 2016; 11(6), e0158156 
Suleiman J, Zingman BS, Diaz RS, Ramalho Madruga JV, DeJesus E, Slim J, Mak C, Lee E, 
McCarthy MC, Dunkle LM, Walmsley S. Vicriviroc in combination therapy with an optimized 
regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial. The 
Journal of infectious diseases. 2010 Feb 15;201(4):590-9. 
Thompson M, Lalezari J, Saag M, Jacobson J, Zingman B, Stambler N, D'Ambrosio P, Maddon P, 
Olson W, Morris S. Weekly and biweekly subcutaneous PRO 140 demonstrates potent, sustained 
antiviral activity. In16th Conference on Retroviruses and Opportunistic Infections 2009 Feb 8 (pp. 
8-11). 
US Food and Drug Administration. Noncirrhotic Nonalcoholic Steatohepatitis With Liver 
Fibrosis:Developing Drugs for Treatment Guidance for Industry. December 2018. 37256dft.docx 
Zobair M. Younossi, F. The epidemiology of nonalcoholic steatohepatitis. Clin Liver Dis 
(Hoboken), 2018; 11(4), 92–94. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 95 of 96 
 
 
16 APPENDIX 
 
16.1 APPENDIX 1: 
ACCEPTABLE METHODS OF CONTRACEPTION 
 
 
 
Barrier Methods 
Intrauterine Device Methods 
Hormonal Methods 
 Male condom plus 
spermicide 
 Cap plus spermicide 
 Diaphragm plus 
spermicide 
 Copper T 
 Progesterone T 
 Levonorgestrel-releasing 
 Implants 
 Hormone shot or 
injection 
 Combined pill 
 Minipill 
 Patch 
NOTE: choice of contraception should be discussed with primary treating physician to discuss 
the risks and benefits of different modalities of contraception. 

Protocol # CDI-NASH-01 
Final Version 7.0 
Date: 14-Jun-2021 
CONFIDENTIAL 
Page 96 of 96 
 
 
 
16.2 APPENDIX 2: 
COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS V5.0 
 
 
For complete detailed information please refer to the link below: 
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Re 
ference_8.5x11.pdf